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SOMMARIO 
INTRODUZIONE La malaria insieme a tubercolosi e AIDS è una delle più diffuse 
malattie infettive al mondo con più di 650.000 morti e 200 milioni di casi clinici 
all’anno. Nei casi di malaria severa, si può manifestare nei pazienti la sindrome da 
insufficienza respiratoria acuta (MA-ARDS) caratterizzata da un’intensa e diffusa 
infiammazione a livello polmonare, con danni alla parete alveolare e vasale, edema 
e infiltrato cellulare, principalmente di monociti/macrofagi. Questi contengono 
pigmento malarico (o emozoina, Hz) noto per stimolare il rilascio di citochine e di 
altri mediatori dell’infiammazione. Nella MA-ARDS sono anche presenti disfunzioni 
a livello di diversi organi, tra cui il fegato.Nei casi di ARDS non malarica, sono state 
descritte alterazioni del surfattante polmonare che possono portare all’aumento 
della tensione superficiale e al collasso alveolare. I principali compiti del surfattante 
sono quelli di ridurre la tensione superficiale e regolare la risposta immune locale. Il 
surfattante è costituito da due frazioni: una definita LA e cioè “large aggregate”, 
ritenuta la frazione attiva; e un’altra definita SA “small aggregate” che costituisce la 
frazione meno attiva. Non è noto se anche nella MA-ARDS siano presenti 
alterazioni del surfattante e come possano contribuire alla gravità della sindrome e 
influire sull’andamento della risposta infiammatoria.  
SCOPO Lo scopo del lavoro è stato quello di descrivere i cambiamenti fisio-
patologici nella MA-ARDS, studiare la risposta infiammatoria sistemica e locale e 
analizzare i cambiamenti lipidici del tessuto polmonare, del surfattante, del fegato e 
del plasma utilizzando due modelli di malaria nel topo con gravità simile, ma 
diverso interessamento di organi interni. In particolare, sono stati usati topi 
C57BL/6J infettati con due specie di Plasmodio: Plasmodium berghei NK65 
(PbNK65) che causa la patologia polmonare e Plasmodium chabaudi (PcAS) che 
non causa complicanze polmonari. I due modelli hanno permesso di paragonare 
direttamente la stessa infezione e individuare gli aspetti caratteristici che potranno 
indirizzare nuove strategie terapeutiche nella MA-ARDS.  
RISULTATI E DISCUSSIONE 
Analisi macroscopica e funzionale del tessuto polmonare nei due ceppi. I 
polmoni dei topi infettati con PbNK65, ma non quelli con PcAS, si presentano 
edematosi, aumentati in peso e di color bruno a causa di microemorragie e della 
deposizione di aggregati di Hz. Solo nei polmoni dei topi con PbNK65 si è 
osservata un’aumentata espressione di citochine, tra cui TNF-α e IFN-, indotta 
quindi specificatamente durante la MA-ARDS e non dovuta all’infezione malarica. 
Questo è confermato dalla osservazione che nei topi trattati con desametasone 
(DEX) si registra un aumento della sopravvivenza, una diminuzione dell’edema 
polmonare e dell’infiltrato di cellule CD8+ senza una riduzione della parassitemia. Il 
tessuto polmonare dei topi con PbNK65 presenta un aumento dei fosfolipidi (PL) 
totali e degli esteri del colesterolo (ChoE) caratterizzati da un elevato rapporto 
acido linoleico/oleico tipico dei ChoE plasmatici. Il trattamento con DEX riporta il 
profilo lipidico alla norma. Questi risultati indicano che l’infiltrazione di lipoproteine 
plasmatiche e l’edema interstiziale sono responsabili delle variazioni del pattern 
lipidico del polmoni. Il trattamento con DEX migliora la patologia polmonare perché 
interviene sulla risposta infiammatoria. Analisi proteica e lipidica del surfattante 
e del plasma dei topi infetti. Il surfattante dei topi infettati con PbNK65 presenta 
un aumento delle proteine rispetto a quello dei topi controllo (CTR) o infettati con 
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PcAS, probabilmente dovuto all’aumento delle proteine plasmatiche che vengono 
incorporate in microstrutture presenti nell’ipofase alveolare. È noto che questo 
comporta una diminuzione dell’attività del surfattante stesso. Il contenuto totale di 
PL non varia in nessun gruppo, ma cambia significativamente il profilo dei singoli 
PL in entrambe le frazioni di surfattante. Sia la frazione LA che SA dei topi con 
PbNK65 presentano un aumento di sfingomielina (SM) e una diminuzione di 
fosfatidilglicerolo (PG). Questi cambiamenti, presenti solo nei topi PbNK65, 
potrebbero essere dovuti ad una alterata sintesi e degradazione dei PL da parte 
delle cellule alveolari danneggiate. 
I livelli plasmatici di PL e trigliceridi (TG) sono significativamente maggiori nei topi 
PbNK65 rispetto ai topi CTR o infettati con PcAS. Nei topi PbNK65 aumentano 
tutte le classi di PL ad eccezione della lisofosfatidilcolina. Queste alterazioni 
plasmatiche potrebbero essere dovute ad alterazioni dell’attività degli enzimi 
coinvolti nel metabolismo lipoproteico. Il profilo degli acidi grassi plasmatici 
presenta livelli elevati di acido docosaesanoico (DHA) sia nei topi PbNK65 che 
PcAS, e questo aumento è solo parzialmente diminuito dal trattamento con DEX. 
Questo suggerisce che l’aumento di DHA non sia dovuto alla complicanza 
polmonare ma piuttosto alla patologia malarica. Analisi del fegato di topi infetti. 
L’ipotesi che l’aumento di TG e di PL plasmatici fosse dovuto ad un’aumentata 
lipogenesi epatica è stata confermata analizzando il fegato dei topi infetti e CTR. Il 
fegato dei topi PbNK65 presenta maggiori livelli di TG e ChoE e un aumento del 
rapporto acido linoleico/arachidonico probabilmente dovuto all’alterazione della via 
di allungamento/desaturazione degli acidi grassi. Sono anche presenti nel tessuto 
maggiori livelli di Hz che giustificano il TNF-α elevato. E’ noto infatti che Hz stimola 
le cellule di Kuppfer a produrre citochine infiammatorie. Sia Hz che TNF-α 
promuovono perossidazione lipidica come confermato dagli elevati livelli di 
malonildialdeide trovati negli omogenati di tessuto epatico. Negli stessi campioni, 
negli stadi più avanzati della patologia, si sono osservati anche bassi livelli di 
glutatione e degli enzimi antiossidanti a conferma dell’elevato stress ossidativo a 
cui il tessuto è stato sottoposto. 
CONCLUSIONI Lo studio presenta per la prima volta un’analisi approfondita delle 
alterazioni lipidiche e della risposta infiammatoria in diversi organi in due modelli 
murini di MA-ARDS. I dati suggeriscono che anche nella malaria, come in altre 
patologie non infettive, esiste un interplay patologico e metabolico polmone-fegato. 
Nei topi PbNK65, l’Hz depositata nei polmoni e il conseguente stato infiammatorio 
sono fondamentali per la patologia polmonare inducendo aumento di infiltrato e di 
citochine, e cambiamenti nella composizione lipidica del surfattante e del tessuto 
polmonare. La patologia polmonare è associata ad alterazioni delle lipoproteine 
plasmatiche che sembrano derivare dalla disfunzione epatica a sua volta causata 
dai depositi di Hz che inducono i macrofagi a produrre TNF-α e ROS. Ne consegue 
perdita di funzionalità epatica, aumento della lipogenesi e alterazione dei lipidi 
plasmatici a loro volta responsabili delle variazioni polmonari. Questi risultati 
confermano che la malaria è una malattia multisistemica e che la co-
somministrazione di farmaci anti-infiammatori e anti malarici potrebbe essere utile 
nel combattere la malattia e le sue complicanze. 
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ABSTRACT 
INTRODUCTION Malaria is a major health problem, with more than 650.000 
deaths and 200 million clinical cases each year. Respiratory distress as malaria 
associated acute respiratory distress syndrome (MA-ARDS) is a common 
complication. The pathogenesis of MA-ARDS is mainly inflammatory and one of 
the main observation is the presence of abundant monocytes and macrophages 
inside the blood capillaries, in the interstitium and also in alveolar spaces. Malaria 
pigment or haemozoin (Hz) is often seen in these cells reflecting active 
phagocytosis and leads to the production of cytokines and other inflammatory 
mediators. Multiple organ dysfunctions are described in MA-ARDS, including liver 
damages. ARDS in non malarious patients is often associated with disorders of the 
lung surfactant, which can lead to the increase in surface tension, alveolar collapse 
and loss of the liquid balance in the lungs. Surfactant is known to reduce the 
surface tension at the air–liquid interface of lung epithelia and to regulate the local 
host immune response. It can be separated into a surface active Large Aggregate 
fractions (LA), representing a reservoir for the surface film located at the air-liquid 
interface of the alveoli and a less surface active, Small Aggregate fraction (SA). It 
is not known at present if alterations of the surfactant also exist in MA-ARDS and 
how they may contribute to the pathology and the development of the inflammatory 
response. 
AIM The aim of our studies was to perform a comprehensive analysis of the local 
and systemic inflammatory response present in MA-ARDS and to analyse the lipid 
profile of the pulmonary surfactant, the lung and liver tissues and plasma using two 
different models of murine malaria of similar gravity, but different involvement of 
lungs or liver. In particular, we studied C57BL/6J mice infected with two different 
species of Plasmodium: Plasmodium berghei NK65 strain which induces MA-
ARDS and Plasmodium chabaudi (PcAS), which does not. The two models allowed 
us to directly compare the different pathological manifestation of the same infection 
in order to identify peculiarities which could be exploited for novel therapeutic 
interventions. 
RESULTS AND DISCUSSION 
Macroscopic and functional analysis of lung tissues in the two strains. The 
lungs of PbNK65 infected mice were swollen, increased in weight and with a dark 
brown aspect due to micro haemorrhages and to the deposition of Hz clusters in 
concentrations significantly higher compared to the lungs of mice infected with 
PcAS. The expression of TNF-α and IFN- was increased only in PbNK65 mice, 
indicating that these cytokines are induced specifically during MA-ARDS and are 
not a consequence of malaria infection. This hypothesis was confirmed by the 
decrease of lung weight and of the CD8+ cells infiltrate, and the reduction /delay in 
mortality rates seen in PbNK65 mice treated with DEX without a concomitant 
reduction in parasitaemia. Therefore, DEX seems to ameliorate MA-ARDS, not by 
inhibiting parasite growth but rather by modulating the immunopathology and the 
inflammatory response. A significant increase of the total phospholipid (PL) content 
and cholesterol esters (ChoE) was observed in PbNK65 lungs and was reverted by 
DEX. Moreover, compared to the control mice (CTR), the fatty acid distribution of 
lung ChoE was characterized by higher levels of the polyunsaturated fatty acid and 
an high linoleic/oleic ratio typical of plasma ChoE. All these features confirm a strict 
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correlation between the interstitial oedema and the infiltration of plasma 
lipoproteins during MA-ARDS. Protein and lipid composition of surfactant and 
plasma of infected mice. The total bronchoalveolar lavage (BAL) of PbNK65 mice 
showed a significant increase in the protein levels compared to CTR or PcAS mice, 
probably due to plasma derived proteins being incorporated into or associated with 
microstructures in the alveolar hypophase. This event is known to decrease the 
intrinsic surface activity of surfactant. The total content of PL was not different from 
CTR, whereas the PL profile of the LA and SA fractions in PbNK65 infected mice 
showed a significant increase in the amounts of sphingomyelin and a decrease in 
phosphatidylglycerol. These changes were absent in PcAS mice and may be 
related to the altered re-uptake and synthesis of PL by injured cells or to PL 
contamination due to inflammatory cells. The plasma levels of PL and 
triacylglycerol (TG) were significantly higher in PbNK65 mice than in CTR or PcAS 
mice. Compared to PcAS or CTR mice in PbNK65 group all the PL classes were 
significantly increased with the exception of lisophosphatidilcholine (LisoPC) that 
was decreased. These plasma alterations may be related to an impaired activity of 
the enzymes involved in the lipoprotein metabolism during infections or 
inflammatory diseases. The most important observation, both in PbNK65 and PcAS 
mice, was the significant increase of docosahexahenoic acid (C22:6 n-3, DHA) 
compared to CTR, which was only partially reverted by DEX treatment, suggesting 
that the increase of DHA is not related to lung pathology but rather to the malaria 
infection. Analysis of the liver tissue of infected mice. The hypothesis that the 
higher PL and TG content of PbNK65 plasma might be due to an enhanced hepatic 
lipogenesis was confirmed by the higher TG and ChoE content of the liver of 
PbNK65 mice compared to PcAS and CTR. An increased ratio linoleic 
(LA)/arachidonic acid (AA) was also present possibly due to the impairment of the 
elongation/desaturation pathway from LA to AA acid. Higher levels of Hz, 
compared to PcAS, were present in PbNK65 mice and, in agreement with the Hz 
capability of stimulating Kupffer cells, we found higher levels of TNF-α. Both Hz 
and TNF-α can induce lipoperoxidation as confirmed by the elevated levels of 
malondialdehyde (MDA) in the liver of PbNK65 mice. This finding was paralleled by 
the lower content of glutathione and of antioxidant enzymes particularly in the late 
stage of the pathology.  
CONCLUSIONS This is the first time that a comprehensive analysis of the lipid 
content and inflammatory response of different organs in a model of murine MA-
ARDS has been performed. All together the data suggest that in MA-ARDS as in 
other severe non infectious pathologies, a pulmonary-liver metabolic interplay exist 
which may contribute to the pathology. In PbNK65 mice, Hz and the derived 
inflammation play an important role in the lung pathology inducing changes in the 
lipid composition of lung and surfactant, cellular infiltration and cytokine production. 
Lung pathology is associated with liver disorders and alterations in the lipoprotein 
profile. Hz accumulation may induce macrophages to produce TNF-α and ROS 
that can interfere with liver functions by inducing lipogenesis and affecting the lipid 
profile of liver and plasma, which in turn contribute to the altered lipid composition 
of the lung tissue. These results confirm that severe malaria is a multi-organ 
dysfunction in which inflammation has an important role in different organs and 
thus, in addition to antimalarial treatment, adjunct therapies with anti-inflammatory 
drugs can be envisaged. 
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ARDS= acute respiratory distress syndrome 
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CM= cerebral malaria 
CTR= control 
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G6PD= glucose 6 phosphate dehydrogenase 
GR= glutathione reductase 
GSH+GSSG= total glutathione 
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HDL= high density lipoprotein 
HDP= haeme detoxification protein 
HL= hepatic lipase 
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SOD= superoxide dismutase 
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1 INTRODUCTION 
1.1 Malaria disease 
Malaria is the most deadly parasitic infection of humans. Although 
economic development and the implementation of control measures during 
the twentieth century have eliminated malaria from many areas of the 
world, the disease is still rampant in the tropics and in the poorest regions 
of the globe, affecting 3 billion people and killing up to 1 million annually 
(World Health Organization, malaria report, 2012) 
Malaria is a parasistic disease transmitted by the bite of an infected female 
mosquito of more than 30 Anopheles species and caused by five species of 
parasites of the genus Plasmodium that affect humans: P. falciparum, P. 
vivax, P. ovale, P. malariae and P. knowlesi. Malaria due to P. falciparum 
is the most deadly form and it predominates in Africa; P. vivax is less 
dangerous but more widespread, and the other three species are found 
much less frequently. Globally, an estimated 3,3 billion people were at risk 
of malaria in 2011, with populations living in sub-Saharan Africa having the 
highest risk of acquiring malaria: approximately 80% of cases and 90% of 
deaths are estimated occur in the African Region, with children under five 
years of age and pregnant women most severely affected (World Health 
Organization, malaria report, 2012). 
In such areas, changes in environmental, economic, or social conditions 
(heavy rains after drought, large population movements together with a 
breakdown in malaria control and prevention services often because of 
armed conﬂicts) can result in epidemics, with substantial mortality in all age 
groups (1). 
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Figure 1- Malaria cases by country. Data source: WHO, Malaria Report 2012 
Malaria is an entirely preventable and treatable disease, provided the 
currently recommended interventions are properly implemented. These 
include: vector control through the use of insecticide-treated nets, indoor 
residual spraying and, in some specific settings, larval control; 
chemoprevention for the most vulnerable populations, particularly pregnant 
women and infants; confirmation of malaria diagnosis through microscopy 
or rapid diagnostic tests for every suspected case; timely treatment with 
appropriate antimalarial drugs according to the parasite species and drug 
resistance. 
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1.2 The malaria parasite life cycle 
The symptoms of malaria are caused by cycles of parasite multiplication 
inside host erythrocytes, and various complications, including cerebral 
malaria, result from cytoadherence of infected erythrocytes to endothelia. 
The P.falciparum parasite life cycle comprises two stages: the first (sexual 
phase) takes place in the Anopheles mosquito vector and the second one 
in the human host (asexual phase) (Figure 2).  
 
 
 
Figure 2- The malaria parasite life cycle (Parasite Image Library) 
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The malaria parasite life cycle involves two hosts. During a blood meal, a 
malaria-infected female Anopheles mosquito inoculates sporozoites into the 
human host (Point 1, Figure 2). Sporozoites infect liver cells (Point 2, 
Figure 2) and mature into schizonts (Point 3, Figure 2), which rupture and 
release merozoites (Point 4, Figure 2). After this initial replication in the liver 
(exo-erythrocytic schizogony; Point [A], Figure 2), the parasites undergo 
asexual multiplication in the erythrocytes (erythrocytic schizogony; Point 
[B], Figure 2). Merozoites infect red blood cells (Point 5, Figure 2). The ring 
stage trophozoites mature into schizonts, which rupture releasing 
merozoites (Point 6, Figure 2). Some parasites differentiate into sexual 
erythrocytic stages (gametocytes) (Point 7, Fiure 2). Blood stage parasites 
are responsible for the clinical manifestations of the disease. The 
gametocytes, male (microgametocytes) and female (macrogametocytes), 
are ingested by an Anopheles mosquito during a blood meal (Point 8, 
Figure 2). The parasites' multiplication in the mosquito is known as the 
sporogonic cycle; (Point [C], Figure 2). While in the mosquito's stomach, 
the microgametes penetrate the macrogametes generating zygotes (Point 
9, Figure 2). The zygotes in turn become motile and elongated (ookinetes) 
(Point 10, Figure 2) which invade the midgut wall of the mosquito where 
they develop into oocysts (Point 11, Figure 2). The oocysts grow, rupture, 
and release sporozoites (Point 12, Figure 2), which make their way to the 
mosquito's salivary glands. Inoculation of the sporozoites into a new human 
host perpetuates the malaria life cycle (Point 1, Figure 2). 
Malaria is transmitted when a female mosquito, infected with P.falciparum, 
takes a blood meal from a human. The parasites, at the stage of motile 
sporozoites, are injected from the salivary glands of the infected mosquito 
and travel to the liver via the microvasculature, a process that occurs over a 
few minutes. In the liver parasites develop into hepatic trophozoites and 
undergo asexual reproduction forming many merozoites which are 
5 
 
enclosed in small packages of host cell membrane termed merosomes. 
This asymptomatic hepatic stage of infection usually lasts about 10-12 
days. Hepatic cell rupture leads to merozoites release into the blood stream 
where they invade circulating erythrocytes of the human host and embark 
upon the clinically important “intra-erythrocytic cycle” of asexual replication, 
which is ultimately responsible for all the clinical symptoms associated with 
the disease. This part of the parasite life cycle produces 8-20 new 
merozoites every 48-72 hours, causing parasite numbers to rise rapidly to 
level as high as 1013 per host. Following invasion of a red blood cell (RBC), 
the merozoite matures into a “ring stage” parasite, so called for the ring-like 
morphology of the parasite on a Giemsa smear. P. falciparum differs from 
other human malaria species in that parasitized erythrocytes do not remain 
in the circulating blood for their entire life cycle. In fact after 24-32 hours, 
when young parasites mature from the ring to the trophozoite stage, 
parasitized RBCs (pRBCs) adhere to endothelial cells in the 
microcirculation of various organs (sequestration), including the brain. 
Trophozoites in the host RBC degrade haemoglobin (Hb) and accumulate 
the breakdown product haemozoin (Hz), also called “malaria pigment”. At 
36-48 hours trophozoites mature into schizonts which undergo the division 
(schizogony) of a single schizont into 16-32 individual merozoites. pRBC 
rupture leads to merozoite release that invade fresh erythrocytes to 
perpetuate the asexual life cycle. In response to poorly understood signals, 
some of the intra-erythrocytic parasites commit to sexual reproduction and 
differentiate into male and female gametocytes in the blood of their host. 
Gametocytogenesis can be triggered in vitro by cooler temperatures or an 
increase in pH, however, in nature, it may also involve a chemical cue from 
within the mosquito (2). 
Upon ingestion by a feeding female mosquito, the gametocytes fuse in its 
midgut and the resulting ookinete invades the midgut wall where it will 
6 
 
develop into an oocyst. The cycle is completed when the division of the 
oocyst produces a large numbers of infective sporozoites which migrate to 
the salivary gland of the mosquito ready to be injected into a host during a 
blood meal, thereby ensuring the continuation of the parasite life cycle 
(Figure 2). 
1.2.1 The intra-erythrocytic cycle of Plasmodium 
How P.falciparum survives in the human host erythrocyte? 
The mature human red blood cell (RBC) is a terminally differentiated cell. It 
lacks subcellular organelles (such as a nucleus or secretory structures) and 
de novo protein/lipid biosynthesis. RBCs contain high concentrations of 
cytoplasmic haemoglobin (about 5mM) and a deformable submembrane 
cytoskeleton, which reflects the specialized functions of erythrocytes for 
delivering oxygen to tissues and surviving repeated passage through 
capillaries. To maintain erythrocyte function in circulation, clearance of 
older RBC and production of new ones are carefully coordinated to 
optimize the delivery of oxygen to tissues. Because erythrocytes lack 
endocytic machinery, parasites attach and enter erythrocytes via several 
pathways by different ligand–receptor interactions. The study of the 
erythrocyte-malaria parasite interaction shows that both parasite and 
erythrocyte components regulate parasite entry and intracellular growth by 
extensively remodeling host membranes. These remodeling events include: 
the invagination of the host cell membrane during parasite entry that results 
in the creation and maintenance of a parasitophorous vacuolar membrane 
(PVM) that surrounds the intracellular organism; the development of 
antigenic, structural, and transport alterations during intracellular parasite 
development. 
Malarial erythrocyte remodelling events presumably occur at a significant 
cost to the human host because many of the associated processes have 
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been linked to clinical evidence of severe disease. The malaria parasite has 
developed a number of ways to ensure its survival in the RBC. After 
invasion the parasite faces a number of biochemical challenges, some of 
which arise through its own metabolism. When merozoites invade the host 
RBCs they grow by ingesting the host cell cytoplasm. Haemoglobin (Hb), 
ingested via a cytostome through an endocytic process, is digested in a 
specialized acidic organelle (the digestive or food vacuole, analogous to 
phagolysosomes of mammalian cells) through the combined action of at 
least two aspartic proteases (plasmepsins I and II) and one cysteine 
protease (falcipain) (3). 
It has been hypothesized that the parasite degrades Hb to obtain building 
blocks for protein synthesis, maintain osmotic balance and to provide space 
for its own growth (Figure 3). Four molecules of haem [ferrous-
protoporphyrin IX, Fe(II)PPIX] are released from each molecule of Hb when 
digested by the malaria parasite. It is commonly accepted that, in the 
presence of molecular oxygen in the parasite food vacuole, Fe(II)PPIX is 
oxidized to form Fe(III)PPIX (FP) following a Fenton-Haber-Weiss-type 
reaction: at that time, a cascade of events begins, on one hand, to prevent 
haem toxicity and on the other hand, to scavenge the reactive oxygen 
species produced. Free FP is highly toxic, inhibiting enzymes and 
destabilising membranes via detergent-like effects and via catalysis of lipid 
peroxidation (4-6). 
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Figure 3- Haemoglobin degradation in the food vacuole of Plasmodium falciparum 
To avoid the toxic effects of a product that arises through its own 
metabolism, the parasite sequesters free FP into a crystalline form termed 
haemozoin (Hz) or malaria pigment (Figure 4). The crystal forms via the 
coordination of the central iron atom of one molecule to one carboxyl of the 
adjacent molecule (7). 
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Figure 4-Haem detoxification: haemozoin formation 
This non-enzymatic process is known as biocrystallization (8) and although 
it is not completely understood, it appears that lipids, the digestive vacuole 
membrane, and the acid environment play a crucial role for the organized 
aggregation of haem monomers into Hz crystals (9, 10).  
Recently, a parasite protein, the Haem Detoxification Protein (HDP), has 
been described, which seems to be involved in accelerating the conversion 
of haem into Hz (11). With a 1–10% parasitaemia, as much as 0,2–2,0 g Hz 
may be produced by P. falciparum during each cycle (12). At the end of the 
cycle, erythrocytes rupture, and Hz crystals are liberated along with the 
daughter merozoites into the blood stream. Hz is rapidly ingested by 
phagocytic cells such as macrophages present in many organs, especially 
in the liver and spleen. HZ can be observed as a dark crystal by light 
microscopy (Figure 5). 
 
 
HAEM HAEMOZOIN  
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Figure 5-Hz in an infected red blood cell (red arrow). By light microscopy, HZ can 
be observed as a dark-brown crystal (B) 
1.2.1.1  Why is Hz important? 
Hz is important as an antimalarial drug target, in diagnostic applications 
and it appears to be biologically active, especially as an immune modulator. 
Hz formation is the target of the classic quinoline group of compounds (13, 
14), and it may even play a role in the mode of action of artemisinins (15, 
16). These drugs may act inhibiting Hz growth by formation of haem drug 
adducts (17) by interfering with nucleation of the crystal or by binding to the 
Hz crystal surface, thus preventing further growth (13). Different binding 
strengths or binding preferences of antimalarial drugs to the different faces 
of the crystal may explain the different inhibitory potency of antimalarial 
drugs on Hz growth (13). 
The detection of Hz is also useful in the diagnosis of malaria, especially in 
methods that make use of its birefringent and paramagnetic properties (18, 
19). Additionally, several studies reported a correlation of Hz-containing 
B 
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monocytes and granulocytes with disease severity, especially an increase 
in the severe forms of malaria (20-22). 
An increasing number of studies recently demonstrated that Hz has intrinsic 
biological activity especially on the immune system. Several groups 
reported an increased pro-inflammatory effect (23, 24). Other studies 
reported a positive correlation between Hz-containing monocytes or 
granulocytes and malarial anaemia (25-27) or an association between 
increased levels of Hz in pulmonary tissue with malaria-associated acute 
respiratory distress syndrome (MA-ARDS) in a mouse model (28). Hz has 
also been reported to have an adjuvant effect, possibly mediated through 
Toll-like receptor 9 (TLR9) (29). Some have questioned if biological effects 
are caused by Hz itself or by other bio-molecules that might be bound to 
Hz, especially DNA (30). For example, conflicting results were presented 
on whether Hz alone or DNA bound to Hz interacts with TLR9 to enhance 
innate responses (30, 31). Others reported that proteins, such as 
fibrinogen, bind to Hz and cause a strong initial stimulation of reactive 
oxygene species (ROS) production and an increase in the levels of TNF-α 
and MCP-1 (monocyte chemoattractant protein-1) in in vitro experiments 
(32). One study reported that synthetic Hz alone appeared inactive and 
only showed effects in the presence of RBC ghosts (which mainly consist of 
the membrane); this finding  was interpreted as an interaction between Hz 
and RBC lipids (33). The finding that attached molecules, rather than the 
Hz crystal itself, cause biological effects finds support in the strong 
adsorptive properties of Hz (34). In fact, Hz crystals tend to stick to each 
other, and sometimes researchers resort to extensive sonication to 
disperse Hz before in vitro experiments (29, 35). 
Other contradictory results have been reported, for example, concerning 
nitric oxide (NO) and ROS production (33, 36, 37). One study concluded 
that human monocytes containing Hz do not release NO (36), whereas a 
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different result was observed with murine macrophages (37). Hz was also 
found to either enhance or inhibit dendritic cell maturation (38).  
Certainly, a possible explanation for these discrepant results could be the 
widely varying experimental protocols, including diverse types and origins 
of phagocytic cells, variable incubation times with Hz, or different types of 
Hz (23, 24). 
1.3 Genetics of malaria disease 
No infectious disease has shaped the human genome more than has 
malaria. The geographic distributions of sickle cell disease, haemoglobins 
C and E, ovalocytosis, thalassaemias, and glucose-6-phosphate 
dehydrogenase (G6PD) deficiency are roughly similar to that of malaria 
before the introduction of control measures, which suggests that these 
disorders confer a survival advantage in the presence of malaria (39). 
Malaria protective mechanisms include decreased parasite growth at low 
oxygen tensions (haemoglobin AS [HbAS]), reduced cytoadherence 
(haemoglobins AC [HbAC] and CC [HbCC] and HbAS), reduced invasion 
(ovalocytosis), reduced parasite densities (G6PD deficiency), and reduced 
multiplication at high densities (haemoglobin AE [HbAE]) (40-42). The 
immune response to malaria is incompletely understood. Non-specific host 
defence mechanisms control the infection initially. Subsequent strain-
transcending and strain-specific immune responses then struggle against 
parasitic antigenic variation to eliminate the blood-stage infection. Both 
humoral and cellular immunity contribute to protection. Eventually, 
exposure to sufficient strains confers protection from illness, but not from 
infection (premonition). Asymptomatic parasitaemia is common in adults 
and older children living high-transmission areas (43). 
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1.4 Pathogenesis of malaria 
In P. falciparum malaria, protuberances or knobs emerge on the infected 
erythrocyte’s surface 12–15 h after invasion. These protuberances extrude 
high-molecular-weight, antigenically variant, strain-specific adhesive 
proteins (PfEMP1) that mediate cytoadherence (attachment to endothelial 
surface receptors in veins and capillaries). Of the potential receptors 
identified, ICAM1 is probably the most important in the brain, chondroitin 
sulphate A in the placenta, and CD36 in most other organs (44). Infected 
erythrocytes adhere to the vessel walls and sometimes to each other (45) 
or to uninfected erythrocytes (rosetting) (46). Adherence causes 
sequestration of RBCs containing mature parasites into vital organs 
(particularly the brain), where the sequestered parasites interfere with 
microcirculatory flow and metabolism and the functioning of vascular 
endothelium (47). As a result, only the younger ring form P. falciparum 
parasites circulate in falciparum malaria, and thus peripheral parasite 
counts the total number of parasites in the body. Other malarias are not 
sequestered substantially, so all developmental stages are noted in 
peripheral blood smears. 
P. vivax, P. ovale, and P. malariae invade RBC selectively (eg, P. vivax 
invades only young erythrocytes), and parasitaemias are usually less than 
1%; P. falciparum and P. knowlesi are less selective and can reach very 
high parasite densities (48). The host responds to malaria by augmenting 
splenic immune function and filtrative clearance, accelerating removal of 
both parasitised and uninfected erythrocytes (49). Schizont rupture 
releases parasite and host cellular material into the blood, which activates 
monocytes and macrophages and induces the release of pro-inflammatory 
cytokines, causing fever and other pathological effects (50, 51). 
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1.5 Recurrent or persistent malaria 
Blood-stage infection can persist for months or years (or decades in P. 
malariae infections) when untreated. Waves of asexual parasitaemia and 
gametocytaemia result from antigenic variation. In tropical regions, P. vivax 
relapses typically every 3–4 weeks (or every 6–8 weeks after treatment 
with slowly eliminated drugs, which suppress the first relapse). In temperate 
areas, P. vivax can remain latent for 8–10 months between primary 
infection and first relapse (52). Recurrent falciparum and vivax malaria 
have pronounced adverse effects in young children, and interfere with 
growth, development, and schooling. 
1.6 Clinical features 
In endemic areas malaria is often the most common cause of fever. The 
first symptoms of malaria are non specific, and include a vague absence of 
wellbeing, headache, fatigue, muscle aches, and abdominal discomfort, 
which are followed by irregular fever. Nausea, vomiting, and orthostatic 
hypotension occur frequently. Generalised seizures are associated 
specifically with falciparum malaria and might be followed by coma 
(cerebral malaria). Most patients with uncomplicated infections have few 
abnormal physical findings other than fever, mild anaemia, and, after 
several days, a palpable spleen. The liver can become enlarged, especially 
in young children, whereas mild jaundice is more likely in adults. In young 
children living in regions in which transmission is stable, recurrent infections 
cause chronic anaemia and splenomegaly. The manifestations of severe 
falciparum malaria depend on age (53). Severe anaemia and 
hypoglycaemia are more common in children, whereas acute pulmonary 
oedema, acute kidney injury, and jaundice are more common in adults; 
coma (cerebral malaria) and acidosis occur in all age groups (Figure 6). 
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Figure 6-Manifestations of severe falciparum malaria by age (A) and mortality in 
children associated with coma, convulsion, acidosis and uraemia (B). 
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Mortality rises when the proportion of infected erythrocytes (parasitaemia) 
exceeds 2%, although the relation between parasite density and prognosis 
in falciparum malaria is very variable. When treated promptly with effective 
antimalarial drugs, uncomplicated falciparum malaria has a mortality of 
roughly 1%. 
1.6.1 Cerebral malaria 
In fatal cases of cerebral malaria, many cerebral capillaries and venules are 
packed tightly with parasitised erythrocytes, whereas other adjacent 
vessels are not obstructed (1, 54, 55). A distinct and specific malarial 
retinopathy with haemorrhages and retinal and vessel whitening occurs 
both in children and in adults. Organ-specific and systemic blood lactate–
pyruvate ratios are increased in proportion to the severity of illness (a 
different profile compared to the hyper-metabolism of sepsis) (56). All these 
findings suggest that extensive microvascular obstruction and impaired 
perfusion are the crucial pathophysiological processes. Little 
histopathological evidence of inflammation is noted, although leucocytes 
are more prominent in the cerebral vessels of African children than in those 
of Asian adults who died from cerebral malaria (57, 58). A mild, generalised 
increase in systemic vascular permeability is noted. The blood–brain barrier 
is functionally intact (59) although the results of autopsies of African 
children suggest some increase in permeability, with disruption of 
endothelial intercellular tight junctions. 
1.6.2 Severe anaemia 
Severe anaemia is the main manifestation of severe malaria in young 
children in areas of high transmission (60) and is usually the cumulative 
result of repeated infections. Accelerated splenic removal of mainly the 
uninfected RBCs and erythrocyte destruction at parasite schizogony are 
compounded by ineffective erythropoiesis (61, 62). Slight coagulation 
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abnormalities are frequent, and thrombocytopenia is usual even in 
uncomplicated malaria (a normal platelet count should lead clinicians to 
question the diagnosis of malaria). Substantial bleeding from disseminated 
intravascular coagulation in severe malaria is rare. Haematemesis from 
stress ulceration or acute gastric erosions can occur. Malarial anaemias are 
classified as uncomplicated (Hb<110 g/l, haematocrit <33%) or severe 
(Hb<50 g/l, haematocrit <15%). Anaemia may become worse after 
treatment begins, particularly if the parasitaemia is high. The anaemia is 
typically normocytic and normochromic, with a notable absence of 
reticulocytes, although microcytosis and hypochromia may be present due 
to the very high frequency of α and β thalassaemia trait and/or iron 
deficiency in many endemic areas. 
1.6.3 Pulmonary oedema 
Acute respiratory distress syndrome (ARDS) is a feared complication in 
adults with severe falciparum malaria (particularly in pregnant women), 
which can also occur in P. vivax and P. knowlesi infections (63, 64). 
Increased pulmonary capillary permeability develops in as much as 30% of 
adult patients and often manifests after the start of antimalarial treatment 
(65, 66). Pathogenesis is not fully understood, but inflammation-mediated 
endothelial damage might have an important role. The role of pulmonary 
vascular parasite sequestration is unclear. Careful fluid management is 
essential; in the absence of mechanical ventilation, the mortality of acute 
respiratory distress syndrome exceeds 80%. With mechanical ventilation, 
case fatality still exceeds 50% in falciparum malaria. 
1.6.4 Acute kidney injury 
Acute kidney injury is common in adults with severe malaria (Figure 6). It 
behaves clinically and pathologically like acute tubular necrosis. 
Pathogenesis remains unclear, but reduced microcirculatory flow probably 
18 
 
contributes (67). Acute kidney injury is frequently associated with 
dysfunction of several other vital organs (leading to high mortality) or can 
develop more slowly as other disease manifestations resolve. Acute kidney 
injury is oliguric in 60–70% of cases. In survivors, urine flow resumes in a 
median of 4 days, and serum creatinine concentrations return to normal in 
a mean of 17 days (68). Early haemofiltration or dialysis substantially 
improves outcomes, especially in acute hypercatabolic renal failure (69). 
Oliguric renal failure is rare in children, although increased concentrations 
of blood urea are frequent and an independent risk factor for death in 
African children with severe malaria (Figure 6 b). 
1.6.5 Malaria in pregnancy 
In areas of high transmission, the risk of low birth weight (<2,5 kg) is 
roughly double when women have placental malaria; the effect is greatest 
during the first pregnancy. This lower birth weight is associated with 
increased infant mortality (70). Maternal anaemia is exacerbated, but most 
mothers remain asymptomatic despite intense accumulation of infected 
erythrocytes in the placental microcirculation. Congenital malaria occurs in 
roughly 5% of neonates but clears spontaneously in 62% of cases (71). 
Maternal HIV infection predisposes pregnant women to malaria and 
exacerbates reductions in birth weight (72). In areas with unstable malaria 
transmission, pregnant women are at increased risk of developing severe 
falciparum malaria with a very high mortality rate (roughly 50%). High 
parasitaemias, severe anaemia, hypoglycaemia, and acute pulmonary 
oedema are all more frequent in pregnant than in non-pregnant women. In 
severe disease, foetal distress, premature labour, and stillbirth often occur. 
The risk of infant death is particularly high if maternal malaria occurs during 
late (near-term) pregnancy (73). Maternal death from haemorrhage at 
childbirth is correlated with malaria-induced anaemia (74, 75). 
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1.7 Diagnosis and assessment 
Thick and thin blood film microscopy examination remains the gold 
standard for diagnosis, but simple, sensitive, and specific antibody-based 
rapid diagnostic tests that detect PfHRP2, species-specific lactate 
dehydrogenase (LDH) or aldolase antigens in finger-prick blood are now 
used widely (World Health Organisation, Malaria Report 2011). PfHRP2-
based tests might remain positive for weeks after acute infection, which 
limits usefulness in high transmission areas, but can be used to diagnose 
severe malaria in patients who have taken artemisinin derivatives and 
cleared peripheral parasitaemia (tests remain strongly positive). PfHRP2-
based rapid diagnostic tests are as good as is routine microscopy in the 
diagnosis of falciparum malaria. The new-generation tests based on 
detection of plasmodium LDH are effective for diagnosis of both falciparum 
and vivax infections, although sensitivity is low at P. vivax densities of less 
than 200 μL. Aldolase based tests are less sensitive, especially for non-
falciparum species (World Health Organisation, Malaria Report 2011). 
Because of their simplicity and speed, rapid diagnostic tests are particularly 
valuable in epidemic investigations and surveys. However, they are 
expensive and do not quantify parasitaemia.  
1.8 Prevention 
1.8.1 Vaccination 
Much time, effort, and money have been spent on the development of 
malaria vaccines. The RTS,S subunit vaccine, which targets the 
circumsporozoite protein of P. falciparum and is boosted with the potent 
ASO1 adjuvant, is the most advanced vaccine in development. The active 
substance in RTS,S vaccine is a recombinant antigen expressed in 
Saccharomyces cerevisiae coded RTS,S. The RTS,S antigen consists of 
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two proteins, RTS and S, that spontaneously assemble into mixed 
polymeric particulate structures intracellularly. The results of a large 
multicentre study of RTS,S (A phase 3 trial of RTS,S/AS01 malaria vaccine 
in African infants) in infants aged 6–12 weeks at first immunisation 
(deployed as a monthly dose for three months in conjunction with an 
expanded programme of immunisation vaccines) showed good safety but 
only moderate efficacy, with 30% protection against clinical malaria and 
26% protection against severe malaria in the 12 months after the last dose. 
Previously reported results (76) in slightly older children (aged 5–17 
months) were better, with 55% protection against all falciparum malaria and 
35% protection against severe malaria during 14 months. 
1.8.2 Vector control 
Vector control is an essential component of prevention. In areas of 
moderate or high transmission in Africa, employment of pyrethroid-
insecticide-treated mosquito nets reduced all cause mortality by roughly 
20% in children younger than 5 years (77). Wide-scale employment of such 
nets has contributed substantially to the fall in malaria morbidity and 
mortality. In addition of protecting the user, insecticide-treated nets protect 
the community by killing anopheline mosquitoes (the so-called mass effect) 
(78, 79), and should be employed in all areas where malaria is endemic. 
They are usually very effective; however, in some parts of Asia, the main 
mosquito vectors bite outside early in the evening or morning and so the 
protective effect is small. Use of pyrethroids in agriculture and widespread 
employment of insecticide-treated nets has put a tremendous selection 
pressure on anopheline mosquitoes and resistance has emerged. 
Indoor residual spraying with insecticides that persist and kill mosquitoes is 
an important component of malaria control (80-82). Its efficacy strongly 
depends on the behaviour of the local Anopheles vectors (whether the 
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mosquitoes enter houses and rest there) and whether resistance has 
emerged. Dichlorodiphenyltrichloroethane (DDT) is still effective in parts of 
Asia and Africa and used for indoor residual spraying, which can result in 
high human exposure (83). Only four general insecticide classes exist, and, 
in some areas, the development of resistance is undermining the efficacy of 
insecticide-based measures (84). 
1.8.3 Chemoprophylaxis and chemoprevention 
Chemoprophylaxis is recommended for travellers during potential exposure 
to malaria (85). For drugs that do not have activity against the pre-
erythrocytic (liver) stage, chemoprophylaxis is given during exposure and 
for four weeks thereafter to catch any blood-stage infections that emerge 
from the liver. Recommendations for chemoprophylaxis depend on local 
patterns of susceptibility to antimalarials and the likelihood of acquisition of 
malaria. When uncertainty exists, drugs that effectively prevent infection 
with resistant P. falciparum should be used: iatovaquone–proguanil, 
doxycycline, primaquine or mefloquine. Chemoprophylaxis is never 
completely reliable, and malaria should always be a possible diagnosis in 
febrile patients who have travelled to endemic areas. 
Previously, chemoprophylaxis was recommended for pregnant women in 
endemic areas, but in most areas resistance has developed against the 
drugs approved for this indication (ie, chloroquine, proguanil). In Africa, 
intermittent preventive treatment with sulfadoxine–pyrimethamine was 
given instead. A full course of sulfadoxine–pyrimethamine twice during later 
pregnancy provided partial protection. A minimum of three doses of 
sulfadoxine–pyrimethamine are now recommended to provide continuous 
preventive effects. Resistance to sulfadoxine–pyrimethamine is increasing 
in Africa, and thus alternative drugs are being investigated for use in 
intermittent preventive treatment in pregnancy. 
22 
 
All pregnant women in endemic areas should be encouraged to attend 
regular antenatal clinics (when available). Pregnant women travelling to 
endemic areas should be advised of the potential risks. Mefloquine is the 
only drug recommended for chemoprophylaxis in pregnant women 
travelling to areas with drug-resistant malaria, and is thought to be safe in 
the second and third trimesters of pregnancy; data for first-trimester 
exposures (although few) are reassuring (86). 
The safety of other prophylactic antimalarials in pregnancy has not been 
established, although no harmful effects have been associated with 
atovaquone–proguanil (WHO: Guidelines for the treatment of malaria, 2nd 
edn. Geneva: WHO Press, 2010) 
The intermittent treatment approach has been extended to infancy, where it 
can be delivered to all at-risk infants via the system in place for the 
expanded programme on immunisation. However, many malaria-related 
diseases and deaths in Africa occur in children aged 3 months-5 years in 
the Sahel sub-region during 4 months of the rainy season. WHO has 
recommended administration of monthly amodiaquine and sulfadoxine–
pyrimethamine (maximum four doses) to all children aged 3 months-5 years 
in this region from the start of the yearly transmission season (WHO: 
Guidelines for the treatment of malaria, 2nd edn. Geneva: WHO Press, 
2012). This seasonal malaria chemoprevention has superseded intermittent 
preventive treatment in infants. Intermittent preventive therapy is effective 
when delivered through schools or to adults at high risk of malaria (87). 
Since the 1930s, various approaches to treatment of whole populations 
have been taken. Mass drug administration to millions of people was 
effective in some settings but not in others and gained a poor reputation 
(perhaps undeservedly); thus this approach has been little used in recent 
years (88). 
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1.9 Treatment 
1.9.1 Severe disease 
Severe falciparum malaria is a medical emergency, and necessitates 
intensive nursing care and careful management. In Asia, parenteral 
artesunate significantly reduced mortality from 22,4% to 14,7% compared 
with quinine. In Africa, artesunate significantly reduced mortality from 
10,9% to 8,5% compared with quinine (89). Intravenous or intramuscular 
artesunate is thus the treatment of choice for severe malaria worldwide 
(including in patients with severe vivax and knowlesi malaria) (World Health 
Organisation: Guidelines for the treatment of malaria, 2nd edn. Geneva). 
Artesunate has no important local or systemic adverse effects, although 
high cumulative doses (≥6 mg/kg per day) can temporarily suppress bone 
marrow. Delayed haemolysis starting a week after artesunate treatment for 
severe malaria has been noted in travellers (particularly those initially 
presenting with high parasitaemias) returning to hospitals in non-endemic 
countries (90). This haemolysis is probably partly caused by the loss of 
once-infected erythrocytes, which results from splenic pitting of parasites 
killed by artesunate. 
In a large placebo-controlled trial community-based pre-referral treatment 
with a rectal formulation of artesunate for patients unable to take oral 
medications decreased malaria mortality in severely ill children by 25% 
(91). 
In acute renal failure or severe metabolic acidosis, haemofiltration or 
haemodialysis should be started early (69). Dose reduction of artemisinin 
derivatives is unnecessary, even in renal failure. Prophylactic 
anticonvulsants are potentially dangerous; high-dose phenobarbital (20 
mg/kg) doubled mortality in children with cerebral malaria—patients died 
mainly from respiratory arrest (92). 
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In unconscious patients, blood glucose should be measured every 4–6 h 
and dextrose continuously infused to maintain concentrations higher than 4 
mmol/l. Hypoglycaemia (<2,2 mmol/l) should be treated immediately with 
bolus glucose. Parasite counts and haematocrit concentrations should be 
measured every 6–12 h. Anaemia develops rapidly in severe malaria; if 
haematocrit falls to less than 20% (haemoglobin <70 g/l), then packed cells 
or whole (preferably fresh) blood should be transfused carefully. The 
transfusion threshold for children in Africa (where anaemia is very common 
and safe blood for transfusion is scarce) is a haematocrit concentration of 
15% or less (haemoglobin concentrations less than 50 g/l). Renal function 
should be checked daily. Management of fluids is difficult, especially in 
adults, because the risks of overhydration (pulmonary oedema) have to be 
balanced against those of underhydration (exacerbation of renal 
impairment and tissue hypoperfusion). Large fluid boluses are harmful at all 
ages (66, 93). Early enteral feeding in non-intubated comatose adults can 
cause aspiration pneumonia, so feeding should not start until the third day 
of the coma (94). When the patient can take tablets reliably, a full course of 
artemisinin combination treatment should be given (World Health 
Organisation: Guidelines for the treatment of malaria, 2nd edn. Geneva). 
Intravenous antimicrobials should be given to all children with suspected 
severe malaria in areas of moderate or high transmission (95). Convulsions 
should be treated with intravenous or rectal benzodiazepines and 
respiratory support provided when necessary. Aspiration pneumonia should 
be suspected in any unconscious child or adult patient with convulsions, 
particularly when persistent hyperventilation is noted. Hypoglycaemia or 
septicaemia should be suspected after sudden deterioration for no obvious 
reason during treatment. Patients who bleed spontaneously should be 
given packed red blood cells with fresh frozen plasma or, when unavailable, 
fresh blood and parenteral vitamin K. 
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1.9.2 Uncomplicated falciparum malaria 
Artemisinin combination treatment is the recommended first-line therapy for 
uncomplicated falciparum malaria in all endemic areas, and is highly 
efficacious against the other human malarias. The artemisinin component 
(artesunate, artemether, or dihydroartemisinin) is given for 3 days with a 
slowly eliminated antimalarial, preferably in a fixed-dose combination. 
Artemisinin combination treatment is rapidly and reliably effective, 
associated with few adverse effects, and curative in more than 90% of 
cases (except in foci of artemisinin resistance) (International Artemisinin 
Study Group, 2004, Lancet). The price of such treatment has dropped 
substantially, making it more generally affordable. Unfortunately, fake or 
substandard antimalarials are widespread in many Asian and African 
countries, which compromises effectiveness, selects for resistance, and 
diminishes confidence in the health sector. Atovaquone–proguanil is highly 
effective everywhere, but seldom used in endemic areas because of the 
cost and propensity for high-grade resistance to emerge from single 
mutations in the cyt b gene. The duration of post-treatment prophylaxis 
after artemisinin combination treatment varies. Slowly eliminated partner 
drugs, such as mefloquine and piperaquine, provide 4–6 weeks 
prophylaxis, whereas reinfections after treatment with artemether–
lumefantrine often emerge within a month. In low transmission areas, a 
single gametocytocidal dose of primaquine (0,25 mg/kg) should be added 
to all artemisinin combination treatments for falciparum malaria (except for 
those in infants and pregnant women, in whom primaquine is not 
recommended) to sterilise the infection and prevent onward transmission 
(World Health Organisation, Global Malaria programme, 2012). Testing for 
G6PD deficiency is not necessary with this dose. Patients should be 
monitored for vomiting for 1 h after any oral antimalarial dosing. If the 
patient vomits, another dose should be given. Minor adverse effects (eg, 
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nausea, abdominal discomfort, headache, dizziness) occur frequently in 
malaria, and often result from the illness rather than the treatment. Three 
days artemisinin combination regimens are well tolerated, although 
mefloquine is associated with increased rates of vomiting and dizziness. 
The frequency of serious adverse neuropsychiatric reactions to mefloquine 
is around one per 1000 patients treated in Asia but as high as one per 200 
in African and white patients. All the antimalarial quinolines (ie, chloroquine, 
mefloquine, and quinine) exacerbate orthostatic hypotension, and are 
tolerated better by children than by adults. 
1.10 Resistance 
Western Cambodia and the Thailand–Myanmar border, where artemisinin-
resistant P. falciparum has emerged, (96, 97) are the regions of greatest 
concern. Resistance to both chloroquine and sulfadoxine–pyrimethamine 
emerged previously in this area, and in both cases the resistance genes 
spread to Africa and caused millions of deaths. Artemisinin-resistant 
parasites are cleared slowly from the blood after artemisinin combination 
treatment. Parasite clearance times exceed 3 days, and treatment failure 
occurs more often. Resistance to amodiaquine, sulfadoxine–
pyrimethamine, and, to a lesser extent, mefloquine, limits deployment of 
artemisinin combinations containing these drugs in several areas. 
1.11 Malaria and lung involvement  
Lung involvement in malaria has been recognized for more than 200 
hundred years, yet our knowledge of its pathogenesis and management is 
limited. 
The lung contributes crucially to two stages of the Plasmodium life cycle. 
First, the initial generation of hepatocyte derived merozoites is released into 
the pulmonary microvasculature, which places the lung at the intersection 
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between the clinically silent liver phase and the symptomatic blood phase 
of the infection (98). Second, the lung is subject to a severe manifestation 
of malaria: Acute lung injury (ALI)/Acute Respiratory Distress Sindrome 
(ARDS), which is characterized by impairment of oxygen exchange due to 
widespread inflammation of the alveolar microvasculature. 
After the maturation of Plasmodium in the infected hepatocytes, the first 
generation of merozoites is released into the microvasculature of the liver 
as merosomes, and they are shuttled out of the liver unharmed, by-passing 
the gauntlet of highly phagocytic Kupffer cells, and travel to the lungs where 
they are arrested and efficiently cleared from the bloodstream. After a 
period of most likely several hours, the merozoites are released from the 
merosome into the pulmonary bloodstream. One possible explanation for 
the high efficiency with which the lung clears merosomes from the blood is 
mechanical trapping (98). Merosomes may be arrested, based on their 
large size, within the pulmonary arterioles, i.e. before being able to enter 
the narrow alveolar capillary bed of the lung. This hypothesis is supported 
by the fact that the average diameter of extrahepatic merosomes (around 
13-18 μm) clearly exceeds the 1–4 μm functional diameter of alveolar 
capillaries. However, merozoites that bud from hepatocytes are also much 
larger than the hepatic sinusoids (around 7 μm), but exit the liver 
nevertheless (98, 99). Mechanical trapping could result if merosomes were 
to become more rigid prior to entering the lungs. Arguing against this, are 
ex vivo lung imaging data showing merosomes easily adapting to the 
narrow vascular lumen of small pulmonary vessels (Leberl and Frevert, 
unpublished data), suggesting that merosomes retain the flexibility needed 
to squeeze through the pulmonary capillary bed if otherwise unrestricted. 
Alternatively, the merosomal membrane may contain Plasmodium-derived 
adhesion molecules that bind to the microvascular endothelium. This 
mechanism, even if not selective for the pulmonary endothelium, would 
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explain the high efficiency of merosome clearance from the blood, as the 
lung represents the first capillary bed, merosomes encounter after leaving 
the liver. The exact site of merosome arrest in the alveolar 
microvasculature is currently under investigation (98, 99). 
1.11.1 Respiratory symptoms and signs of MA-ARDS 
A dry cough may be present in 20% to 50% of patients with malaria (100-
102). Tachypnea may result from high fever, anaemia, and lung 
involvement. Lung function tests have demonstrated small airways 
obstruction and a decrease in diffusion capacity in uncomplicated 
falciparum and vivax malaria (63, 101, 103). The reduced diffusion capacity 
is attributed to a reduction in the pulmonary capillary vascular component of 
gas transfer, which could be related to the sequestration of parasitized 
erythrocytes in the pulmonary microcirculation. The alveolar-capillary 
membrane component of gas transfer was reduced progressively in the 
days following treatment, consistent with the development of pulmonary 
interstitial and alveolar oedema. Pulmonary oedema is the most severe 
form of lung involvement. Increased alveolar capillary permeability leading 
to intravascular fluid loss into the lungs is the main pathophysiologic 
mechanism (65). Pulmonary oedema has been described most often in 
non-immune individuals with Plasmodium falciparum infections as part of a 
severe systemic illness or as the main feature of acute malaria. 
P. vivax and P. ovale have also rarely caused pulmonary oedema. It was 
presumed that P. vivax infection may lead to severe consequences only 
when possibility of mixed infections exists and the pulmonary 
manifestations were so far under-diagnosed (104). Different types of 
respiratory distress may be present in malaria patients. Hyperventilation 
occurs as a consequence of metabolic acidosis, mainly due to lactic acid 
accumulation (105). The pathogenesis of a raised blood lactate in severe 
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malaria is almost certainly multifactorial. High levels of TNF are associated 
with high blood lactates in childhood malaria but the relationship between 
TNF-α and the presence of acidosis remains unclear (106, 107). 
Lactate production by the parasite is also considered to be quantitatively of 
only minor importance and the lack of association between peripheral 
parasitaemia and blood lactate supports this conclusion (108). Lactate in 
addition can be produced by peripheral tissues, in particular when anaemia 
and/or blood vessel obstruction by sequestering parasites cause hypoxia.  
Metabolic acidosis may be aggravated by renal dysfunction and insufficient 
clearance of lactic acid. The lower blood pH stimulates the brain stem to 
increase the respiratory rate to expel more carbon dioxide, resulting in 
hyperventilation. Currently, it is not clear whether hyperventilation may 
contribute to pulmonary oedema (e.g., by prolonged high tidal volume 
breathing), although both may occur simultaneously (104). Hyperventilation 
is the main type of respiratory distress in African children with malaria and 
is also frequent in adults (109, 110). 
A completely different type of respiratory distress are ALI and ARDS. ARDS 
is a disease with a high mortality and is a common cause of admission into 
intensive care units (ICUs) all over the world. 
ALI and ARDS have well-defined criteria for diagnosis based on reduced 
ratio of partial pressure of arterial oxygen/inspired fraction of oxygen -PaO2 
/FiO2 ratios- (PaO2/FiO2 < 200 mm Hg, or PaO2/FiO2 < 300 mm Hg for the 
less severe ALI), bilateral infiltrates on the chest radiograph, and absence 
of left atrial hypertension. ARDS is the most cruel pulmonary manifestation 
of severe malaria, irrespective of the infecting species. ALI/ARDS may be 
seen as part of a severe multisystem illness or may be the main clinical 
feature and often occurs within a few days of starting treatment when 
parasitaemia is falling. This is illustrated well by Krishnan and Karnad, who 
showed that at presentation, 84 of 301 patients (28%) had mild hypoxia 
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(PaO2 /FiO2 ratios, 400 mm Hg), 18 ALI, and 10 ARDS. ARDS developed in 
a further 33 patients within 48 hours and in 36 patients after 48 hours (111). 
Dyspnea in patients developing ARDS may start abruptly, progress rapidly, 
and causes death within hours of onset. Physical signs include sweating, 
tachypnea, labored breathing, peripheral and central cyanosis, inspiratory 
crepitations, expiratory wheezes, and frothy sputum. An increased 
respiratory rate and dyspnea are usually the earliest signs. The jugular 
venous pulse is not raised unless there is concomitant fluid overload. 
Hypoxia-related confusion and agitation may also be seen. 
1.11.2 Epidemiology of MA-ARDS 
Reliable epidemiological data are not available regarding the prevalence of 
ALI/ARDS in patients with malaria. Data from different studies suggest that 
about 5% patients with uncomplicated falciparum malaria and 20% – 30% 
patients with severe and complicated malaria requiring ICU admission, may 
develop ARDS. It should be remembered, however, that different 
denominators have been used in various publications and meaningful 
comparison of such data is not possible. Furthermore, in many of the 
previously reported studies, the precise definition used for the diagnosis of 
ARDS is also not mentioned (112). 
MA-ARDS occurs mainly in adults; most reported ARDS cases are from 
low-transmission area or from non immune travellers, as resident adults 
from high transmission areas are semi-immune and protected against 
severe disease. Also pregnant women with placental malaria are prone to 
develop MA-ARDS (65, 113). 
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1.11.3 Role of concomitant bacterial sepsis 
Bacterial sepsis is an important contributor to the genesis of ALI/ARDS in 
severe falciparum malaria. In patients with severe falciparum malaria, the 
prevalence of bacteraemia in published studies has varied from 6% –15% 
(112). However, an obviously evident focus of sepsis may not be 
discernible in many patients. Further research is required to understand the 
contribution made by bacterial sepsis in patients with severe falciparum 
malaria. This important observation implies that, in endemic areas, 
practicing clinicians should have a low threshold to initiate broad spectrum 
antibiotics in falciparum malaria patients with ALI/ARDS and shock as it can 
be life-saving (113, 114). 
1.11.4 Pathophysiology of MA-ARDS 
The pathogenesis of ALI/ARDS in severe malaria is not understood. There 
are multiple potential causes that may result in lung injury during malaria, 
which may also be interrelated. These include the effects of sequestration 
of parasitized erythrocytes, host immunologic reactions to lung speciﬁc 
sequestration or systemic malaria infection, superimposed pulmonary 
infections (community acquired, nosocomial, or opportunistic in 
immunocompromised patients), aspiration, coexistent sepsis and 
bacteremic induced ARDS, or the effects of treatment such as ﬂuid 
resuscitation. 
The sequestration of pRBCs in the pulmonary microcirculation may initiate 
lung damage via direct endothelial activation and recruitment of host 
inﬂammatory responses, but these can continue after treatment with 
antimalarial drugs. The occurrence of ALI/ARDS when a parasite is 
declining or has been cleared suggests a post-treatment inﬂammatory 
effect as a contributory cause, since parasite products such as malaria 
haemozoin pigment can persist in the vessels either bound to endothelial 
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cells in ghosted ruptured erythrocyte membranes postschizogony or 
phagocytosed by host leukocytes (115). A combination of parasitized 
erythrocyte sequestration and lung inﬂammatory changes are considered 
the main cause of falciparum malaria induced ALI/ARDS. 
Some workers (103) have proposed that ALI/ARDS in malaria is likely to be 
a continuous spectrum from subclinical lung involvement in uncomplicated 
malaria and severe malaria through to ALI/ARDS in severe malaria. The 
authors postulated that in patients with severe malaria without ALI, 
endovascular obstruction caused by erythrocytes with reduced 
deformability, parasitised erythrocytes, and leucocytes; endothelial injury 
and interstitial oedema result in ventilation-perfusion mismatch and 
impairment of gas exchange. Furthermore, worsening or persistence of 
these gas exchange abnormalities after treatment and beyond the expected 
time of clearance of parasitised erythrocytes reflects a prolonged 
inflammatory response and the genesis of ALI/ARDS (103). 
Severe falciparum malaria is characterized by an upregulation of pro 
inﬂammatory cytokines eg, TNF-α (which causes an increase in endothelial 
intracellular adhesion molecule-1 expression), and IL-1, IL-6, and IL-8 
which have also been implicated in the pathogenesis of ARDS. Anti 
inﬂammatory cytokines such as IL-4 and IL-10 are also upregulated, and an 
imbalance between IL-10 and the proinﬂammatory cytokine IL-6 has 
prognostic signiﬁcance for death (116). 
However, none of the cytokine proﬁles in severe falciparum malaria is 
speciﬁcally associated with capillary leakage in the lung. A decrease in 
pulmonary NO production in adults with severe malaria (117), could be 
signiﬁcant for pulmonary capillary leakage, because pulmonary NO is 
central in the modulation of pulmonary vascular tone and pulmonary 
hypertension (118). 
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A relative L-arginine deﬁciency (the precursor of NO) with increased levels 
of asymmetric dimethylarginine (an inhibitor of NO synthase) and an 
increase in free haemoglobin caused by intravascular hemolysis all 
contribute to the decrease in NO bioavailability (119). 
Data from a murine model of severe malaria caused by Plasmodium 
berghei indicate that vascular endothelial growth factor (VEGF) may also 
be involved in damaging alveolar capillary endothelium (120), but levels of 
plasma VEGF in patients with human falciparum malaria are signiﬁcantly 
lower in severe versus uncomplicated cases (121), and in patients with fatal 
cerebral malaria in India, (122), arguing against high levels of VEGF being 
directly associated with lung injury in severe human falciparum malaria. 
 
Figure 7-Cellular components involved in the pathogenesis of malaria-associated 
acute respiratory distress syndrome (MA-ARDS) 
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The sequestration of infected red blood cells (mainly in the schizont stage) 
is supposed to play an important role in the initiation and amplification of 
local immunopathology. Haemozoin crystals are produced by sequestering 
parasites, are also found in phagocytes, and are able to induce pulmonary 
inflammation. Margination and infiltration of inflammatory cells (mainly 
monocytes or macrophages, lymphocytes, and some neutrophils) and 
platelets in blood vessels, interstitial tissue, and alveoli of the lungs are 
crucial determinants of the pathogenesis of MA-ARDS. Damage to and 
apoptosis of endothelial cells results in increased vascular permeability and 
microhaemorrhages. As alveolar oedema and haemorrhages are also 
frequent, it may be inferred that the epithelium is also damaged, which is 
presumably further amplified by the deposition of proteinaceous debris 
(hyaline membrane formation). Alveolar oedema, thickened interstitium, 
and presumably also decreased blood flow result in impaired gas exchange 
and severe hypoxemia. 
1.11.5 Role of inflammation in MA-ARDS  
Variable levels of inflammation are observed in malaria. During MA-ARDS 
abundant leukocyte recruitment and inflammation is evident. Since MA-
ARDS often appears after therapeutic clearance of parasites, it’s supposed 
to result from excessive inflammation. Central to the onset of MA-ARDS is 
a shift of the normal anti-thrombotic and anti-inflammatory state of the 
(tolerant) pulmonary endothelia towards an activated pro-thrombotic and 
pro-inflammatory phenotype with expression of activators of the clotting 
system and adhesion molecules for platelets and leukocytes (123). 
Unlike ALI/ARDS induced by sepsis, the infiltration of inflammatory cells 
into the microvasculature and interstitium of the lung during human malaria 
appears histopathologically as predominantly mononuclear with a lesser 
contribution of polymorphonuclear cells (63, 99, 103, 124). 
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Specifically, during MA-ARDS there is an accumulation of monocytes, 
macrophages and lymphocytes, whereas only limited numbers of neutrohils 
are present (105). Initially, P. falciparum iRBCs bind and roll along the 
microvascular endothelium via interactions with ICAM-1,VCAM-1, PECAM-
1, as well as P and E-selectins, then firmly adhere to endothelial CD36 
(125, 126). The binding of infected RBCs to the pulmonary 
microvasculature activates the endothelium and leukocytes, although the 
relative contribution of the various leukocyte subpopulations remains 
unclear. Endothelial activation results in the release of cytokines and up-
regulation of adhesion molecules, thus perpetuating the inflammatory cell 
recruitment. This then leads to the accumulation of monocytes, which also 
release pro-inflammatory cytokines such as TNF-α and IL-1. TNF-α and IL-
1, in turn, induce IL-6 and IL-8 as well as endothelial cytoadherence by up-
regulating ICAM-1 and VCAM-1, but not CD36 (112, 125, 127). 
Furthermore it’s known that TNF-α and IL-6 increase vascular permeability 
(128), TNF-α reduces the pulmonary expression of the amiloride sensitive 
epithelial sodium channel (ENaC) in the alveoli, altering alveolar fluid 
clearance. Additionally, TNF-α triggers the release of NO, which can reduce 
alveolar epithelial sodium transport by impairing the function of ENaC and 
the sodium/potassium ATPase (129). 
The release and activation of cytokines, such as TNF-α and IL-1 from 
macrophages and monocytes can be due also to Hz deposition in the lung.  
Van de Steen et al demonstrated the important role of Hz in pulmonary 
inflammation by the injection of Plasmodium falciparum-Hz in malaria free 
C57BL/6J mice. Injection of Pf Hz induced the pulmonary expression of the 
neutrophil-attracting chemokine; and stimulated the pulmonary expression 
of cytokines (130, 131). 
Furthermore, Hz inside the phagocytes cannot be degraded and interacts 
with polyunsaturated fatty acids present in membranes resulting in 
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accumulation of different lipoperoxidation products including 4-
hydroxynonenal (4-HNE) and hydroxyeicosatetraenoic acids (HETEs). 
HETEs augment the inflammatory response by inducing the expression of 
pro-inflammatory cytokines and chemokines through the induction of NF-kB 
(132). 
1.11.6 Murine models for MA-ARDS 
Several studies have employed mouse models to study lung pathology 
prior to death from cerebral malaria (CM) (133, 134) or in concert with CM 
(135). Selective models for murine malaria-associated ALI/ARDS have 
provided valuable insights into various pathogenetic mechanisms (120, 
136) and possible interventions (130, 133). 
The most common model to study MA-ALI/ARDS is the infection of mice 
with P.berghei ANKA. This parasite strain causes lethal CM in several 
mouse strains (C57Bl/6, DBA/1, CBA/J) culminating in coma and death 
when peripheral parasitaemia reaches around 10%(137). At the same time, 
mice develop pulmonary pathology characterized by oedema, interstitial 
infiltration of inflammatory cells and limited haemorrhages. However, due to 
CM, mice usually die before completely developing pulmonary pathology. 
An important strategy to avoid the problem of early death and to study MA-
ALI/ARDS is the use of parasite strains that do not cause CM. Infection of 
C57Bl/6J mice with P.berghei NK65 resulted in severe MA-ARDS with 
initial interstitial oedema and cell infiltration and progression to severe 
alveolar oedema, cell infiltration and haemorrhages (130). This model has a 
high incidence and the pathology develops to a full extent without CM, 
creating a sufficient time window to test candidate therapeutic treatments. 
Furthermore, the P.berghei NK65 MA-ARDS model has a high degree of 
similarity with human MA-ALI/ARDS. In particular, leukocyte infiltrations 
consist mainly of inflammatory macrophages and lymphocytes, with only a 
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limited number of neutrophils; hyaline membranes are formed in the alveoli 
and abundant microhemorrages develop. 
The infection of C57Bl/6J mice with Plasmodium chabaudi may cause 
limited pulmonary pathology with lymphocyte infiltration 20 days post 
infection, after the main parasitaemia peak (138). This animal model can be 
useful as negative control to understand if the changes are due to malaria 
disease or to MA-ARDS. 
1.11.7 Interventions and treatment 
There are no ALI/ARDS treatment trials in malaria, so management 
strategies follow non malaria ARDS guidelines (139-141). Mechanical 
ventilation is often difficult in the severely diseased lung. Lung compliance 
is markedly reduced and unevenly distributed, ventilation/perfusion is 
mismatched, and gas diffusion is compromised. Guidelines include the 
application of volume- or pressure- support ventilation with positive end-
expiratory pressure, avoidance of both high tidal volumes (6 mg/kg ideal 
body weight) and an initial plateau pressure, 30 cm H2O (142). 
An early study in murine MA-ARDS indicated a possible beneficial effect of 
phenoxybenzamine, an alpha-blocker and vasodilator. This is in line with 
the oedema promoting role of catecholamines (143). Furthermore, 
indomethacine, an inhibitor of cyclooxygenase-1 and -2, effectively blocked 
the pulmonary oedema, suggesting an important role for prostaglandins in 
murine MA-ARDS. More recently, anti-inflammatory treatments have been 
evaluated in the mentioned mouse models. Inhalation of carbon monoxide 
(CO), which has strong anti-inflammatory effects, decreased serum VEGF 
levels and protected against MA-ALI  (120). The same effect was obtained 
by pharmacological treatment with a novel CO-releasing molecule, ALF492 
(144). 
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Treatment with 80 mg/kg dexamethasone, an inexpensive glucocorticoid, 
greatly inhibited P.berghei NK65 induced MA-ARDS, even when 
administered after appearance of the pathology (130, 139). The problem in 
the use of dexamethasone is the high dosage (80 mg/kg), which exceeds 
the maximum dosage for patients (3-5 mg/kg). More research to 
understand the therapeutic effects of dexamethasone in MA-ARDS is 
underway. 
39 
 
2 AIMS 
Malaria associated acute respiratory distress syndrome (MA-ARDS) is a 
deadly complication and its pathophysiology is insufficiently understood. In 
particular, little is known about the biochemical alterations contributing to 
lung dysfunction. The most commonly used animal model for malaria-
associated ALI/ARDS is infection of susceptible mice (e.g., C57BL/6 mice) 
with PbANKA, in which the critical roles of IFN-γ, IL-12, intercellular 
adhesion molecule-1, urokinase receptor, CD40 and lymphotoxin-a were 
documented (133-135, 145-147). As susceptible mice infected with 
PbANKA die quite rapidly from cerebral malaria, the study of ALI/MA-ARDS 
is possible only in the early phase of the complication. 
Therefore, it was critical to analyze whether MA-ARDS might also develop 
in other mouse models of malaria, for example, without cerebral pathology 
or with a broader time window for the evaluation of the pathology.  
In this study, the occurrence of MA-ARDS in C57BL/6 mice infected with P. 
berghei NK65 (PbNK65) is described and investigated at different levels. 
To deepen our understanding of the complexity of the pathological changes 
in malaria-ARDS we have explored in the murine model of C57BL/6J mice 
infected with PbNK65 the lipid profile of lung tissue and the molecular 
organization and lipid composition of the pulmonary surfactant.  
In parallel, to understand the metabolic networks/pathways related to MA-
ARDS caused by the PbNK65 infection, we have also explored the liver 
and plasma changes in lipid profile. In fact, severe malaria is often 
characterized by multi-organ failure and in particular significant hepatic 
pathology (148-151) and host homeostasis is achieved at the cost of a 
cascade of events in different tissues with liver playing a major role in toxic 
control and helping the organism maintain homeostasis.  
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Plasma/serum composition on the other hand, reflects the status of this 
homeostasis and is also an excellent reporter of disturbances caused by 
environmental stressors.  
The analyses performed on PbNK65 mice have been also performed in 
mice infected with Plasmodium chabaudi (PcAS), a Plasmodium strain that 
does not induce lung pathology. 
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3 MATERIALS AND METHODS 
3.1 Chemical reagents 
Solvents and plates silica gel for High Performance Thin Layer 
Chromatography were purchased from MERCK (Darmstad, Germany). All 
the others chemicals were from Sigma-Aldrich (Italia) unless otherwise 
stated. 
3.2 Mice and parasites 
3.2.1 Infection of Mice with rodent malaria Parasites 
C57Bl/6J mice were infected by intraperitoneal injection of 104 Plasmodium 
berghei NK65 (PbNK65) or Plasmodium chabaudi AS (PcAS) infected red 
blood cells (iRBCs) by serial passage of tail vein blood obtained from a 
mouse that had been infected with PbNK65 or PcAS. The percentage of 
infected erythrocytes in the peripheral blood (parasitaemia) was determined 
by microscopic analyses after Giemsa staining. Mice were sacrificed at day 
8 or 10 post infection, euthanasia was performed by intraperitoneal 
injection of Nembutal and every effort was made to minimize suffering. 
All experiments were approved by the local ethics committee (License 
LA121251, Belgium). 
3.2.2 Treatment of infected mice with dexamethasone (DEX) 
Dexamethasone sodium phosphate (DEX; CERTA, Braine-l’Alleud, 
Belgium) was dissolved in phosphate-buffered saline (PBS) and a volume 
of 200 μl, containing the indicated dose, was injected intraperitoneally daily 
starting at day 6 or 7 post infection, before the onset of MA-ARDS. 
Control mice were treated with the same volume of PBS.  
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3.3 Preparation of biological specimens 
Blood was drawn by cardiac puncture into heparin coated syringes and 
centrifuged at 1850xg for 5 minutes to separate plasma and RBC. 
To asses pulmonary pathology, left lungs were pinched off before 
bronchoalveolar lavage (BAL) and perfusion and were used for lung weight 
and RNA extraction.  
Bronchoalveolar lavage (BAL) fluids was collected from right lungs by 
intratracheal instillation of an isotonic NaCl solution (3 x 0.6 ml) through a 
trachea cannula and immediately centrifuged at 150xg for 10 min at 4°C to 
pellet cells. The cell-free supernatant (total fraction) was collected and 
immediately centrifuged at 12000xg for 30 min to obtain a Large aggregate 
fraction (LA, pellet) and a Small aggregate fraction (SA, supernatant) 
according to Davidson et al. (152). LA and SA fractions were lyophilized, 
resuspended in an appropriate volume of distilled water and stored at  
- 80°C until further processing.  
The percentages of lymphocytes, monocytes/macrophages, and 
neutrophils in the totale BAL were determined by microscopy analysis of 
Cytospin slides (Thermo Shandon, Cheshire, UK). 
To remove circulating iRBCs, mice were perfused with 0.15 M NaCl 
containing 0.2 mM butylhydroxytoluene (BHT) as an antioxidant, and lungs 
and livers were removed and weighed. A small piece of the liver was stored 
at ‐80°C for Hz quantification, whereas the other parts of the liver and right 
lungs were mechanically homogenized in Precellys tubes in 600 μl of a 
solution containing 20 mM Tricine pH 7.5, 250 mM sucrose, 5 mM EDTA, 
0.2 mM BHT and a protease inhibitor cocktail (Sigma).  
Lung homogenates were further centrifuged at 1000xg for 10 min at 4°C, 
washed three times in the same buffer and the pooled supernatants were 
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ultracentrifuged at 100000xg for 1 hour at 4°C. Pellets, representing an 
enriched membrane fraction, were resuspended in a proper volume of 
distilled water added of 0.2 mM BHT and stored at -80°C until further 
analyses. 
3.4 Total lipid extraction and fractionation 
Lipids in plasma, BAL fluids, lung and liver samples were extracted and 
partitioned according to Folch (153). Briefly: lipids were extracted once by 
chloroform/methanol (2:1, v/v), once by chloroform/methanol (1:2, v/v) and 
once by chloroform/methanol (1:1, v/v) . After centrifugation at 20000xg for 
15 minutes at 4°C, the supernatants containing the lipid fraction were 
isolated, dried under a stream of N2, dissolved in a proper volume of 
chloroform and saved at -80°C until further analyses.  
An aliquot of the total lipid extract was fractionated in the different lipid 
components by silicic acid column chromatography according to Vance et 
al. (154), and the neutral fraction was further fractionated according to a 
slightly modified procedure of Horning et al. (155). Briefly: about 1 g of 
silicic acid was resuspended in hexane and slurried in a column of about 
1.0 cm diameter. About 300 to 350 mg of lipids in hexane were separated 
by stepwise elution with the following benzene-hexane mixtures: benzene-
hexane 18% (v/v) and benzene-hexane, 60% (v/v). 
3.4.1 Phospholipid and neutral lipid analyses  
Phospholipid (PL) phosphorus was determined by the Bartlett procedure 
(156). Briefly: dried samples were added with 0.5 ml 80% perchloric acid 
and heated for 90 minutes at 200°C. After the incubation 1.2 ml of Fiske 
solution (30 g of monobasic sodium sulphite + 6 g of dibasic sodium 
sulphite + 0.5 g of 1.2.4 amino naphthol sulfonic acid dissolved in 250 ml of 
distillated water and filtered after 3 hours) and 1 ml of Molibdate solution 
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(200 ml of 2.2 % ammonium molybdate + 14 ml 96 % sulphuric acid diluted 
to 1 l with distilled water) were added, mixed thoroughly and heated for 10 
minutes at 100°C. The optical density at 625 nm was recorded with the use 
of spectrophotometer UV-Visible Cary 50 Scan against a standard curve (2 
μg/0.1 ml of potassium phosphate). 
The individual classes of PL were separated by High Performance Thin 
Layer Chromatography (HPTLC) plates by chloroform/methanol/acetic 
acid/water 60:40:4:2 (v/v/v/v) as developing solvent. Spots were visualized 
by a solution of anisaldehyde (157) and quantified by densitometric 
analysis (Camag Reprostar 3). Cholesterol (Cho), free fatty acids (FFA), 
triglycerides (TG) and cholesterol esters (ChoE) were quantified by 
densitometric analysis after separation by HPTLC in hexane/diethyl 
ether/acetic acid (90:10:1 v/v/v) and visualized with a solution of 10% 
CuSO4 in 8% H3PO4. 
The fatty acid composition of the lipid fractions was analyzed by gas liquid 
chromatography according to Corsetto et al. (158). 
Briefly: the fatty acid methylesters were obtained after derivatization with 
sodium methoxide in methanol 3.33% w/v and injected into gas 
chromatograph (Agilent Technologies 6850 Series II) equipped with a flame 
ionization detector (FID) under the following experimental conditions: 
capillary column: AT Silar length 30 m, film thickness 0.25 μm; gas carrier: 
helium; temperature injector 250°C; detector 275°C, oven 50°C for 2 min, 
rate of 10°C min-1 until 200°C for 20 min. A standard mixture containing 
methyl ester fatty acids was injected for calibration. 
The degree of unsaturation of fatty acids was calculated and expressed as 
double bond index (DBI). DBI represents the sum of the values obtained by 
multiplying the percentage of each fatty acid by the number of double 
bonds in that acid, divided by 100. 
45 
 
3.4.2 Lipid peroxidation 
Lipid peroxidation was measured by determining the levels of thiobarbituric 
acid reactive substances (TBARS) in the sample homogenates according 
to the method of Wey slightly modified as previously reported (159). Briefly, 
sample homogenates (200 μg protein) were added to 500 µl of 2-
thiobarbituric acid (TBA) reagent (6 g TBA dissolved in 4 ml of NaOH 5 N 
and brought to 100 ml in 3% HClO4) and heated at 100 °C for 10 min. After 
cooling TBARS were extracted with 1 N buthanol (Merck). Fluorescence of 
the upper alcoholic phase, separated by a brief centrifugation at 2000 g for 
5 minutes, was determined in a Varian Cary Eclipse spectrofluorimeter 
(Varian instruments, CA, USA) (λ exc= 520 nm; λ em= 553 nm). A standard 
curve was obtained by dissolving tetraethoxypropane in 0.01 N HCl (Merck) 
to produce malondialdehyde (MDA), used as standard compound. Data are 
expressed as pmoles of MDA per micrograms of proteins, evaluated by the 
Bradford protein assay (160). 
3.5 Antioxidant enzymes and other analyses 
Liver homogenates were centrifuged at 12000xg for 10 minutes and 
supernatants were used to determine the activity of antioxidant enzymes 
and total glutathione (GSH+GSSG). Catalase (CAT), glutathione reductase 
(GR) and superoxide dismutase (SOD) activity was determined according 
to Aebi et al (161), Pinto et al. (162), and by a CAYMAN assay kit (Cayman 
chemical, Michigan, USA), respectively, and expressed as mU or U/mg 
protein. 
 
Catalase: Catalase catalyzes the breakdown of H2O2 according to the 
following reaction: 
2 H2O2  2 H2O+O2 
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The rate of decomposition of H2O2 is determined spectrophotometrically by 
measuring the decrease of absorbance at 240 nm (spectrophotometer UV-
Visible Cary 50 Scan). 
 
Glutathione reductase: Glutathione reductase catalyzes the reduction of 
oxidized glutathione (GSSG) by NADPH or NADH to reduced glutathione 
(GSH): 
GSSG + NAD(P)H  2 GSH + NAD(P)+ 
 
The activity of the enzyme is measured by following the oxidation of 
NAD(P)H spectrophotometrically at 340 nm (spectrophotometer UV-Visible 
Cary 50 Scan). 
 
SOD: The assay utilizes a tetrazolium salt for the detection of superoxide 
radicals generated by xanthine oxidase and hypoxantine. One unit of SOD 
is defined as the amount of enzyme needed to exhibit 50% dismutation of 
the superoxide radical. 
 
 
 
Xantine + O2                                         2 O2                                         Formazan dye 
 
H2O2 + Uric Acid                      2 O2 •-                         Tetrazolium salt 
       SOD 
    O2 + H2O2 
 
Scheme of the Superoxide Dismutase Assay 
   XANTINE OXIDASE 
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Total Glutathione (GSH + GSSG): An aliquot of total homogenate was 
precipitated, immediately after preparation, with 1 % (w/v) picric acid. Total 
glutathione was spectrophotometrically determined in the supernatant by 
titration with 5-5’-dithiobis-2 nitro benzoic acid (DTNB) according to Beutler 
(163) and to the following reactions: 
 
              2 GSH + DTNB         Gluthatione Reductase      GSSG + 2 TNB 
     GSSG + NADPH + H+                                   2 GSH + NADP+  
  DTNB + NADPH + H +                                    2 TNB + NADP + 
         GSH-GSSG 
 
Total antioxidant power (PAO): PAO was assessed by the Sigma 
Antioxidant Assay Kit. The principle of the antioxidant assay is the 
formation of a ferryl myoglobin radical from metamyoglobin and hydrogen 
peroxide, which oxidizes the 2,2’-azino-bis (3-ethylbenzthiazoline-6-sulfonic 
acid (ABTS) to produce a radical cation, ABTS°+, a soluble green 
chromogen that can be determined spectrophotometrically at 450 nm 
(spectrophotometer UV-Visible Cary 50 Scan). 
 
Hydroxyproline content: The assay was performed according to Tager AM 
et al. (164). Biefly, 0.5 ml of lung/liver total homogenates were hydrolyzed in 
an equal volume of 6 N HCl at 110°C for 12 h and proper aliquots were 
added with 0.5 ml of chloramine T (Sigma, St. Louis, MO), (1.4% 
chloramine T, 10% n-propanol, and 25% 1 M sodium acetate). After 20 min 
of incubation at room temperature, 0.5 ml of Erlich's solution (14% 1 M p-
dimethylaminobenzaldehyde in 70% n-propanol, 20% perchloric acid) was 
added and a 15 min incubation at 65°C performed. Absorbance was 
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measured at 550 nm and the amount of hydroxyproline was determined 
against a standard curve. 
3.6 Quantitative reverse transcription‐polymerase chain 
reaction (RT- qPCR)  
RT-qPCR was performed in collaboration with the laboratory of Professor 
Philippe Van Den Steen (Leuven, Belgium). In brief, after mechanical 
homogenization of perfused livers, total RNA was extracted with RNAeasy 
Minikit (Qiagen, Hilden, Germany) and quantified with the Nanodrop ND-
1000 (Isogen ife Science, Temse, Belgium). For each sample, cDNA was 
synthesized with the High Capacity cDNA Reverse Transciptase kit and 
quantitative PCR (qPCR) was performed on 25 ng and 12.5 ng cDNA with 
the following mouse-specific primer and probe sets from Apllied Byosistems 
or Integrated DNA Technologies (Leuven, Belgium): IP-10/CXCL10 
(NM_021274.1), TNF (NM_013693.2), IL-10 (NM_010548.1). The qPCR 
was performed with the TraqMan Fast Universal PCR Master Mix (Applied 
Biosystems) on an ABI Prism 7500 Fast Real-Time PCR System (Applied 
Biosystem). As a control form mRNA quantification, 18S ribosomal RNA 
(X03205.1) was also quantified. Since 18S ribosomal RNA levels were 
found to remain stable during the infection, was used to normalize the data. 
3.7 TNF protein determination 
Liver homogenates were centrifuged at 15000 x g for 15 minutes and TNF-
α was assayed in supernatants using the mouse ELISA kit (R&D Systems, 
Minneapolis, MN, USA) following the manufacturer’s instructions. The 
quantity of cytokine was plotted against a standard curve provided by the 
distributor. 
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3.8 HZ extraction and determination 
To assess lung and liver injury, perfused livers and lungs were used for the 
determination of the Hz content by heme‐enhanced chemoluminescence 
according to Deroost et al (165). Analyses were performed in collaboration 
with the laboratory of Professor Van Den Steen (Leuven, Belgium). Briefly, 
30-60 mg of perfused liver or lung were homogenized in minimum 5 
volumes of a solution containing 50 mM Tris/HCl pH 8.0, 5 mM CaCl2, 50 
mM NaCl and 1% of Triton X-100. The homogenate was supplemented 
with 1% Proteinase K and incubated overnight at 37°C. The next day the 
proteinase K digest was sonicated (VialTweeter, Hielscher ultrasonics 
GmbH, Germany) for 1 minute (10W, pulse 0.5 sec) and centrifugated at 
11000xg for 45 min. The supernatant was discarded and the pellet was 
washed three times in 100 mM NaHCO3, pH 9 and 2% SDS with 
subsequent sonication and centrifugation for 30 min to remove degraded 
tissue, free haeme and Hb. After the third wash, the pellet (Hz) was 
dissolved and sonicated in 100 mM NaOH, 2% SDS and 3 mM EDTA to 
form haematin and centrifuged to pellet the any remaining insoluble 
material. To confirm that the isolated was indeed Hz, it was examinated for 
its birefringence character. The extracted Hz was measured in different 
diluitions by luminescence method: 100 µl luminal (100 µg/ml 3 
aminophtalhydrazide) and 100 µl of peroxide (7% tert-butyl hydroperoxide), 
both dissolved in NaOH/Na2CO3 solution, light emitted in the presence of 
Fe3+ (present in the haematin core) was measured during one second using 
a Thermo Luminoskan Ascent apparatus. Peroxide catalysis into oxygen by 
Fe3+ is a fast reaction. Therefore, special care was taken to keep the time 
between the addition of the peroxide and the luminescence measurements 
minimal and as similar as possible between the different wells. A diluition 
series of haematin (10 µM-1.2 nM) was used as a standard. The unknown 
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Hz concentration (nM) was calculated from the calibration curve of the 
haematin concentration (nM) versus luminescence (events/sec). 
The amount of Hz (pmol/mg tissue) was multiplied with the total weight of 
the concerning organ and expressed as pmol or nmol haematin/organ. 
3.9 Histological analyses 
Livers were perfused to remove circulating blood, dilated with 0.75 ml 
neutral buffered formalin solution (4%) by intratracheal instillation with 
subsequent ligation, removed, fixed in the same solution for 24 hours and 
embedded in paraffin. Histological assessment was done by hematoxylin-
eosin staining and immunohistochemistry. Immunohistochemistry was 
performed on paraffin-embedded section with monoclonal anti-mouse 
F4/80 IgG2b (CI: A3-1, Abcam, Cambridge, UK, diluition 1/50). Paraffin 
sections were pretreated with EnVision FLEX Target Retrieval Solution, low 
pH (Dako, Heverlee, Belgium) for 10 min at 97°C. Endogenous peroxidase 
activity was blocked using EnVision FLEX Peroxidase-Blocking Reagent 
(Dako) for 5 min. The sections were incubated with the primary antibodies 
for 30 min at room temperature. Subsequently, slides were incubated with 
peroxidase labelled rabbit anti-mouse (Dako; diluition1/100) to enhance 
sensitivity. Visualization was by reaction with 3.3’-diaminobenzidine wich 
produces a brown color in the presence of peroxide. Negative controls 
consisted of omission of the primary antibody. Transmitted light images 
were taken trough a 40x/1.3 oil Plan-Apochromat objective of an Axiovert 
200 M microscope equipped with AxioCamMRm camera (Zeiss, Gottingen, 
Germany). Image adjustements (Sigma, unsharp masking and gamma) 
were performed with the AxioVision 4.6 software. 
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3.10 Lung leukocytes analyses 
The analyses of leukocytes in lung tissue were performed in Leuven, 
Belgium, at the laboratory of the professor Van den Steen (Rega Institute). 
Leukocytes were isolated from the lungs and counted with a Burker 
hemacytometer (excluding erythrocytes and dead cells), and the relative 
proportions of various leukocyte subclasses were analyzed by 
fluorescence-activated cell sorting. Total number of each subclass were 
calculated by multiplication of the relative proportion with the total leukocyte 
cell numbers. 
3.11 Statistical analysis 
Results are reported as mean ± standard deviation (SD). Comparison 
between groups was performed using Student’s t-test. Differences were 
considered statistically significant when p< 0.05. 
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4 RESULTS 
Pulmonary tissue. The macroscopical analyses of the lungs showed that 
10 days post infection, differently from PcAS mice, the lungs of PbNK65 
infected mice were significantly affected as indicated by the swollen and 
dark brown aspect (Figure 8) and by the increased lung weight (Figure 9). 
CTR PcAS PbNK65
 
Figure 8- Lungs from uninfected mice and mice infected with PcAS or PbNK65 (10 
days post infection) 
The increase in lung weight started 8 days post infection and was 
approximately twofold that in PcAS infected mice at the time of death, with 
peripheral parasitaemia around 20 %. 
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Figure 9- Weights of the lungs of mice infected with PbNK65 or PcAS were 
determinated at various times post-infection (day 8, 9 and 10).  
n=6 for each time point and strain 
The dark brown aspect of PbNK65 mice was due to the deposition of the 
black malaria pigment (Hz): at day 10 post infection we found a significantly 
higher content of Hz in the lungs of P.berghei (PbNK65) mice while in 
P.chabaudi (PcAS) infected mice only traces of malaria pigment were 
present (Figure 10). 
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Figure 10- Hz levels in perfused right lungs. Hz from 30-60 mg of tissue was 
quantified as described in Materials and Methods expressed as pmol Hz/mg lung 
tissue. 
n=10/12;  ***p<0,001 vs CTR. 
PcAS infection was not lethal and did not result in any lung pathology, 
although the parasitaemia of PcAs infected mice at day 10 post infection 
was similar to that of PbNK65 mice (Figure 11). 
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Figure 11- Peripheral parasitaemia of mice infected with PbNK65 or PcAS was 
determinated 6, 8 and 10 days post infection. 
 n=6 
Despite the proven lung pathology of PbNK65 infected mice, in the total 
lung homogenate we did not detect at day 8 or 10 post infection neither 
collagen increase due to fibrotic degeneration as suggested by the normal 
hydroxyproline levels, nor lipoperoxidation products due to oxidative stress 
(data not shown). 
Since Hz has inflammatory properties and a strong pulmonary inflammatory 
response is induced in MA-ARDS, we investigated the expression of some 
cytokines at various times post infection. A significant increase of mRNA of 
TNF-α and IL-10 was detected only in PbNK65 infected mice and not in 
PcAS (Figure 12). 
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Figure 12- Cytokine expression in lungs of PbNK65 or PcAS infected mice. mRNA 
expression was analyzed at different time points by quantitative reverse 
transcription polymerase chain reaction. 
n=4/6 for each time point and each parasite strain. 
The cytokines increase indicated that a pathogenic inflammatory reaction 
caused the pulmonary pathology. Therefore, the effects of treatment with 
dexamethasone (DEX), a common anti-inflammatory glucocorticoid, were 
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evaluated in PbNK65 infected mice. Daily intraperitoneal injection of DEX 
was made starting at day 6 or 7 post infection as described in materials and 
methods. Survival of PbNK65 mice was significantly extended (Figure 13, 
Panel A) and the lung oedema was reduced by DEX treatment (Figure 13, 
Panel B). 
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Figure 13- Panel A: Infected mice with PbNK65 were treated with DEX and 
survival of mice was monitorated daily. n=16 for each group. 
Panel B: Lung weight of PbNK65 or PcAS infected mice and PbNK65 
infected mice treated daily with DEX starting 6 days after the infection. 
n=10; ** p<0,01 vs CTR 
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DEX acted on the cytokine and inflammatory response present in MA-
ARDS decreasing the infiltration of CD8+ cells into lungs and the levels of 
IFN-γ (Figure 14, Panel A and B). 
61 
 
 
A 
0
50
100
150
200
250
CTR PbNK65 PbNK-DEX
To
ta
l c
el
l n
um
be
r *
 1
0^
3
CD8+ lymphocytes
**
 
B 
0
5
10
15
20
25
30
35
40
45
50
CTR PbNK65 PbNK-DEX
m
R
N
A 
fo
ld
 in
cr
ea
se
IFN-ɣ
**
*
 
Figure 14- Panel A: CD8+cells infiltration in lungs of PbNK65 infected mice and 
PbNK65 infected mice treated with DEX. n= 5/7 for each group; **p<0,01 vs CTR. 
 Panel B: Effect of DEX on IFN-γ expression in PbNK65 infected mice 
and in PbNK65 infected mice treated with DEX. n=8/10 * p< 0,05; **p<0,01 vs CTR  
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However, DEX treatment did not reduce the peripheral parasitaemia that 
was, on the contrary, slightly but significantly increased (Figure 15). 
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Figure 15- Peripheral parasitaemia of PbNK65 infected mice treated or not with 
DEX was determined at 10 days post infection by Giemsa staining of blood 
smears. n=10; *p<0,05 vs not treated mice 
The pathogenesis of MA-ARDS in PbNK65 mice was investigated by 
studying the changes in the lipid profile of lung tissue.  
Strain-related differences in the lipid composition were present in the 
membrane enriched fraction of lungs: in PbNK65 infected mice the total 
content of phospholipids (PL) and cholesterol esters (ChoE) was 
significantly higher than in control or in PcAS-infected mice both at day 8 
and 10 post infection, (Figure 16, Panel A and B) and PL increase was 
accounted by the higher amount of phosphatidylcholine (PC), 
corresponding to 30% or 50% of total PL respectively at day 8 and 10 post 
infection (Figure 17). 
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Figure 16- Panel A: Phospholipid content of the lung membrane enriched fraction 
at different times post infection. n=9/15; * p<0,05 vs CTR 
Panel B: ChoE content of the lung membrane enriched fraction at different 
times post infection. n=6; *p<0,05; **p<0,01 vs CTR 
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The content of phosphatidylethanolamine (PE), phosphatidilserine (PS), 
phosphatidilinositol (PI) and sphingomyelin (SM) was similar to that of CTR 
and PcAS groups (Figure 17).  
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Figure 17- PL composition of the membrane enriched fraction of PcAS or PbNk65 
infected mice at day 8 and 10 post infection. 
n=6/7; **p<0,01 vs CTR 
When the analyses were performed in the membrane enriched fraction of 
non perfused lungs the increase of ChoE and PL of PbNK65 mice was 
significantly higherTable 1 and Figure 18). 
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CTR PcAS PbNK65 PbNK-DEX
μg/mg protein 12,68 ± 2,0 31,70 ± 9,5 348,90 ± 43,0** 34,30 ± 5,1  
Table 1- ChoE content of the lung membrane enriched fraction (μg ChoE/mg 
protein) of PcAS or PbNk65 infected mice and PbNK65 infected mice treated with 
DEX. Lungs not perfused n=9/15; **p<0,001 vs CTR 
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Figure 18- PL content of the membrane enriched fraction of PcAS or PbNk65 
infected mice and of PbNK65 infected mice treated with DEX.  
Lungs not perfused 
n=9/15; **p<0,001 vs CTR 
Further, the increase of PL was accounted not only by the higher content of 
PC (370,4 µg/mg protein corresponding to 35,9%) but also by a significant 
increase of PE (417 µg/mg protein corresponding to 40,4%) (Figure 19).  
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Figure 19- PL composition of the membrane enriched fraction of PcAS or PbNk65 
infected mice and PbNK65 infected mice treated with DEX.  
The mice were not perfused 
n=9/15; *p<0,05 vs CTR 
The increase of the total content of PL, in particular of PC and PE (Figure 
18 and Figure 19), and ChoE Table 1) was almost completely reduced by 
the treatment with DEX. 
The fatty acid distribution of the total lung lipids was altered as well at day 
10 post infection, being characterized by higher levels of palmitic (C16:0, n-
7) and docosahexenoic (C22:6 n-3, DHA) fatty acids (Table 2). 
67 
 
Table 2- Percentage distribution of fatty acid in the lung tissue (day 10 post 
infection) 
CTR Pc AS Pb NK65 Pb NK-DEX
C14:1 1,88 ± 1,1 0,81 ±  0,4 1,62 ± 0,8 0,54 ± 0,3
C16:0 33,15 ± 5,5 31,45 ±  9,6 38,78 ± 5,8 * 32,99 ± 8,8
C16:1 3,54 ± 1,0 1,37 ±  0,9 4,78 ± 1,5 2,95 ± 1,3
C18:0 12,50 ± 1,8 13,73 ± 2,4 10,19 ± 2,2 ** 14,03 ± 4,1
C18:1 14,16 ± 1,0 11,85 ± 0,6 10,09 ± 1,4 *** 11,20 ± 1,2 *
C18:2 n-6 12,71 ± 1,6 11,23 ± 1,0 10,21 ± 1,8 ** 11,66 ± 1,2 *
C18:3 α 1,38 ± 1,3 0,42 ± 0,2 1,55 ± 1,6 0,25 ± 0,1
C18:3 γ 1,85 ± 1,4 1,24 ± 0,5 1,50 ± 1,2 0,82 ± 0,1
C20:3 n-6 1,65 ± 0,8 1,62 ± 1,2 1,25 ± 0,6 1,60 ± 0,3
C20:4 n-6 11,82 ± 2,8 15,65 ± 2,5 11,65 ± 2,6 13,97 ± 2,8
C20:5 n-3 0,29 ± 0,2 0,39 ± 0,4 0,22 ± 0,1 0,18 ± 0,2
C22:5 n-3 1,09 ± 0,5 2,06 ± 0,6 0,92 ± 0,2 2,06 ± 0,8
C22:6 n-3 3,93 ± 1,1 8,16 ± 1,4** 7,24 ± 1,6 *** 7,72 ± 0,9 **
PI a 110,10 ±  23,9 160,74 ± 18,2** 130,59 ± 19,4 ** 148,51 ± 20,1 **
* p< 0,05 vs CTR
** p< 0,01 vs CTR
***p< 0,001 vs CTR  
aPI: Relative oxidizability of lipid. The value is calculated based on the relative 
oxidation rate of unsatured fatty acid as follows:  
PI=(%monoenoic x 0,025)+(%dienoic x 1)+(%trienoic x 3)+ (%tetraenoic x 4)+ 
(%pentaenoic x 6)+(%hexaenoic x 8) 
n= 5/11; *p<0,05; **p<0,01; ***p<0,001 vs CTR 
DHA was similarly increased in PcAS-infected mice and not affected by 
DEX treatment. Table 2 also includes the Peroxidability Index (PI) value, 
which is calculated by the formula specified in Table 2 caption. Due to the 
high content of DHA, the PI value of lung tissue from infected mice is 
significantly higher compared to CTR mice indicating a higher relative 
oxidability of the membranes. Preliminary results showed that in PbNK65-
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infected mice higher percentages of DHA are also present in the lung ChoE 
fraction (6,9% vs 3,8% of CTR). The PbNK65 ChoE fraction is also 
characterized by higher levels of linoleic acid (C18:2, n-6, LA= 25,4 % vs 
16,2 % of CTR), arachidonic acid (C20:4, n-6, AA= 26,4 % vs 13,7% of 
CTR) and an higher linoleic/oleic acid (C18:1, n-9) ratio (2,3 vs 1,0 of CTR).  
Brochoalveolar lavage. Since ARDS pathology is often associated with 
surfactant disorder, in the present study we analyzed the bronchoalveolar 
lavage fluid (BAL) from P.berghei and P.chabaudi infected mice. The data 
from BAL analyses further documented the gravity of the lung pathology, 
present especially in PbNK65 group. 
The total (cell-free) BAL fluid of PbNK65-infected mice showed highly 
increased protein levels from day 8 post infection, greater at day 10 post 
infection and absent in PcAS infected mice (Figure 20). 
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Figure 20- Protein content of BAL fluid of PbNK65 or PcAS infected mice at day 8 
or 10 post infection.  
n=4/6; *p< 0,01; ***p<0,0001 vs CTR 
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Considerable number of erythrocytes were observed in the BAL fluid of 
PbNK65-infected mice, showing that haemorrhages had occurred. 
Importantly, leukocyte numbers were strikingly increased in the BAL fluid 
10 days post infection with PbNK65, whereas in PcAS infected mice, BAL 
leukocytes were barely or not increased. The different leukocyte 
subpopulations of BAL fluid were determined by microscopy enumeration of 
Cytospin preparations, and the absolute numbers of macrophages, 
lymphocytes and neutrophils were calculated. All three different cells 
populations were significantly increased already from 8 days post infection 
with PbNK65 (Table 3). 
 
Table 3- Cell numbers in BAL fluids (day 10 post infection) 
CTR PcAS PbNK65
Leukocytes 107,3 ± 10,3 106,1 ± 17,5 668,5 ± 173,1 **
Erytrocytes 31,0 ± 10,0 11,6 ± 3,8 2386,8 ± 898,1 **
Macrophages 103,8 ± 12,4 100,7 ± 19,6 569,5 ± 141,5 **
Neutrophils 1,1 ± 0,3 0,4 ± 0,2 * 28,3 ± 14,3 **
Lymphocytes 2,5 ± 0,5 5,8 ± 1,4 * 68,7 ± 24,6 **  
n=4/6;  ***p<0,0001 vs CTR 
Similarly to the PcAS group, the PL content of PbNK65 infected mice was 
slightly higher compared to CTR at day 8 post infection, although not 
significantly different, and further increased at day 10 (Table 4). The ratio 
protein/PL of total BAL was higher in PbNK65 mice than PcAS at both time 
points (Table 4). 
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Table 4- BAL fluid: total PL content and prot/PL ratio 
ug PL/ml prot/PL
CTR 56,00 ± 5,2 1,71 ± 0,5
PcAS day 8 91,76 ± 32,0 1,06 ± 1,0
PcAS day 10 80,12 ± 50,6 1,09 ± 0,6
PbNK65 day 8 77,63 ± 53,8 8,18 ± 8,05***
PbNK65 day 10 162,30 ± 75,8 10,05 ± 5,5***  
n=4/6;  ***p<0,0001 vs CTR 
The BAL large aggregate fraction (LA) of PbNK65 infected mice was similar 
to that of CTR mice at day 8 and 10 post infection (Figure 21, Panel A), 
showing substantial increases in both protein content (not shown) and 
protein/PL ratio (Figure 21, Panel B). These alterations are absent in the 
PcAS group.  
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Figure 21- Percentage of the total PL (Panel A) and protein/PL ratio (Panel B) of 
BAL large aggregate(LA) fraction at day 8 or 10 post infection in PbNK65 and 
PcAS infected mice. 
n=4/6; ***p< 0,001 vs CTR 
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In addition, in the PbNK65-infected mice the PL profile of LA fraction was 
significantly modified at both days post infection, showing a significant 
increase in the relative amounts of SM and a decrease in 
phosphatidylglycerol (PG) (Figure 22, Panel A). The same changes of the 
PL profile were observed in the small aggregates fraction. In this fraction, 
PG was almost undetectable and lysophosphatidylcholine (LPC) was 
dramatically increased (Figure 22, Panel B). 
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Figure 22- Percentage distribution of PL in LA (Panel A) and SA (Panel B) 
fractions of PbNK65 and PcAS infected mice at day 8 or 10 post infection. 
n=4; *p<0,05; **p<0,001; ***p<0,0001 vs CTR 
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Plasma. Since plasma reflects the status of host homeostasis and is also 
an excellent reporter of disturbances caused by environmental stressors, 
we explored the plasma lipid profile. 
Compared to CTR and PcAS the plasma lipid profile of PbNK65 mice was 
characterized by an higher PL content (Figure 23).  
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Figure 23- PL content in plasma (mg/100 ml) of PbNK65 and PcAS infected mice 
at day 8 post infection. 
n=8/12; **p<0,01 vs CTR 
Specifically, we found a significant increase in SM, PC and PE content in 
PbNK65 infected mice paralleled by lower levels of LysoPC that led to an 
higher PC/lysoPC ratio (Figure 24). 
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Figure 24- PL composition of plasma (mg/100 ml) of infected and non infected mice 
at day 8 post infection.  
n=6/8; *p<0,05; **p<0,01; ***p<0,001 vs CTR 
The neutral lipid content was changed as well. In particular the total 
triacylglycerol (TG) and free cholesterol (Cho) content were significantly 
increased while ChoE content was unchanged in the two different strains 
(Figure 25). 
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Figure 25- Plasma neutral lipid content (mg lipids/mg protein) of infected and non 
infected mice at day 8 post infection. 
n=8/12 *p<0,05; **p<0,01 vs CTR 
The total fatty acid profile of plasma showed in PbNK65-infected mice lower 
levels of linoleic acid (C18:2) and higher levels of arachidonic acid (AA) and 
DHA at both day 8 and 10 post infection (Table 5). Lower levels of C18:3 
and higher levels of AA and DHA fatty acids were also present in the 
purified PL and ChoE fractions (not shown). 
Treatment by DEX only partially reduced the DHA levels (Table 6). 
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Table 5- Plasma fatty acid distribution (%) of PbNK65 or PcAS infected mice at day 
8 and 10 post infection 
CTR PcAS day 8 PcAS day 10 PbNK65 day 8 PbNK65 day 10
C16 23,24 ± 0,1 23,92 ± 0,03 24,68 ± 0,5 18,67 ± 1,0 20,57 ± 0,6
C16:1 1,89 ± 0,1 1,38 ± 0,4 0,55 ± 0,1 * 0,61 ± 0,05 * 0,66 ± 0,05 *
C18 9,94 ± 0,08 10,06 ± 0,1 10,84 ± 1,1 18,22 ± 0,05 13,79 ± 0,06
C18:1 13,46 ± 0,8 13,48 ± 0,01 11,25 ± 1,2 8,03 ± 0,2 9,03 ± 0,2
C18:2 n-6 30,90 ± 0,6 31,36 ± 0,1 31,11 ± 2,5 25,26 ± 0,6 * 25,94 ± 0,6 *
C18:3  γ 0,76 ± 0,5 1,14 ± 0,1 0,94 ± 0,2 0,51 ± 0,01 ** 0,16 ± 0,07 **
C20:3 n-6 1,00 ± 0,01 0,85 ± 0,2 0,66 ± 0,0,1 0,71 ± 0,01 ** 0,41 ± 0,04 **
C20:4 n-6 12,92 ± 1,08 12,28 ± 0,2 14,09 ± 2,3 19,24 ± 0,9 17,98 ± 0,6
C20:5 n-3 0,42 ± 0,01 0,36 ± 0,01 0,33 ± 0,03 0,36 ± 0,01 0,51 ± 0,08
C22:5 n-3 0,40 ± 0,01 0,39 ± 0,03 0,45 ± 0,01 0,31 ± 0,03 * 0,47 ± 0,03
C22:6 n-3 4,52 ± 0,14 4,26 ± 0,2 4,66 ± 0,7 7,74 ± 0,4 ** 10,18 ± 0,4 ***
PI 128,67 ± 8,5 124,48 ± 10,1 133,84 ± 6,1 171,48 ± 9,7 187,25 ± 11,8
C18:2/C20:4 2,70  ± 0,9 2,55 ± 0,05 2,25 ± 0,4 1,31 ± 0,03 1,45 ± 0,1  
n=4; *p<0,05; **p<0,01; ***p<0,0001 vs CTR 
Table 6- Plasma fatty acid distribution (%) of mice infected with PcAS, PbNK65 and 
PbNK65 treated with DEX (day 10 post infection) 
CTR PcAS PbNK65 PbNK-DEX
C16 19,06 ± 2,8 21,71 ± 1,8 18,11 ± 2,2 16,64 ± 1,3 
C16:1 1,90 ± 1,0 1,27 ± 0,4 0,72 ± 1,1 * 0,90 ± 0,5 *
C18 11,75 ± 3,5 10,54 ± 2,3 11,48 ± 2,0 10,71 ± 1,2
C18:1 13,63 ± 1,9 12,98 ± 1,7 13,10 ± 3,7 17,43 ± 3,7
C18:2 n-6 33,02 ± 4,8 30,43 ± 3,7 26,90 ± 0,2 * 31,53 ± 0,8
C18:3  γ 0,98 ± 0,4 0,95 ± 0,2 0,47 ± 0,2 * 1,17 ± 0,2
C20:3 n-6 1,14 ± 0,1 1,17 ± 2,5 0,66 ± 0,3 * 0,69 ± 0,2 **
C20:4 n-6 13,42 ± 4,8 14,13 ± 2,5 16,25 ± 1,9 11,98 ± 1,8
C20:5 n-3 0,49 ± 0,1 0,36 ± 0,1 0,43 ± 0,1 0,36 ± 0,1
C22:5 n-3 0,39 ± 0,02 0,57± 0,1 * 0,59 ± 0,1 ** 0,87 ± 0,2 ***
C22:6 n-3 4,21 ± 1,3 6,48 ± 0,2 * 10,87 ± 1,0 ** 7,26 ± 1,6 **
PI 130,29 ± 28,5 177 ± 21,6 187,78 ± 14,2 * 149,31 ± 14,7
C18:2/C20:4 2,70  ± 0,9 2,18 ± 0,5 1,68 ± 0,4 * 2,69 ± 0,5  
n=5; *p<0,05; **p<0,01; ***p<0,0001 vs CTR 
78 
 
Liver. We also investigated the liver pathology present in PcAS and 
PbNK65 infected mice. The weight of liver was significant increased, at day 
8 post infection, in PbNK65 infected mice and at a greater extent in PcAS 
infected mice, while at day 10 post infection hepatomegaly was present 
only in PcAS group (Figure 26). The content of total protein/gr liver was 
significantly lower, compared to CTR, in both models of infection, with 
levels in PbNK65 mice significantly lower compared to PcAS (p< 0,05) 
(Figure 27). 
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Figure 26- Liver weights of PbNK65 and PcAS infected mice. 
n=6; *p<0,05; **p<0,01; ***p<0,001 vs CTR 
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Figure 27- Protein content (mg protein/g liver) in the liver of infected and not 
infected mice at different times post infection. 
n=6; **p<0,01 vs CTR 
Analogously to lungs, livers from PbNK65-infected mice had a dark-brown 
coloration due to HZ deposition. The amount of malaria pigment increased 
progressively during infection and was higher in PbNK65 group compared 
to PcAS (Figure 28). 
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Figure 28- pmol HZ/mg liver at different time points after infection with PbNK65 or 
PcAS. 
n=5/6; ***p<0,001; ****p<0,0001 vs PcAs day 10 
As shown in Figure 29 the cryosections from perfused livers, stained with 
hematoxylin-eosin, demonstrated larger and more abundant clusters of HZ 
in PbNK65 mice compared to PcAS group. No major morphological 
changes were noticeable in the liver architecture of the two parasite strains.  
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Figure 29- Cryosections were prepared from livers of mice uninfected (Con) and 
infected with PbNK65 or PcAS at day 10 post infection and stained with 
hematoxylin-eosin. Insets show cluster of Hz (dark brown crystals). Representative 
images are shown. 
However, submicroscopical signs of liver fibrosis were evident in PcAS and 
PbNK65 infected mice at day 8 post infection as demonstrated by the 
increased levels of hydroxyproline. However, in both strains, the amount of 
hydroxyproline decreased at day 10 post infection returning to values 
similar to those of CTR group (Figure 30). 
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Figure 30- OH proline content in liver of infected mice at different time points (day 8 
or 10 post infection)  
n=4/9; **p<0,01; ***p<0,0001 vs CTR  
°°°p<0,001 vs PcAS day 8 
In agreement with the high HZ deposition present in the liver of PbNK65-
infected mice we found higher levels of mRNA TNF-α (Figure 31) and TNF-
α protein (Figure 32). 
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Figure 31- TNF-α expression in PbNK65 and PcAS infected mice at different times 
post infection. mRNA expression kinetic was analyzed by quantitative reverse 
transcription-polymerase chain reaction. n=6 
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Figure 32- TNF-α protein in mice infected with PbNK65 or PcAS at day 8 or 10 post 
infection. 
n= 5; * p<0,05; ** p<0,01 vs CTR; °° p<0,01 vs PcAS day 10 
The expression of the inflammatory mediator TNF-α was strictly correlated 
to the HZ deposition in PbNK65 infected mice (Figure 33). 
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Figure 33- Speraman correlation between Hz and TNF-α expression in liver of 
PbNK65 infected mice at day 8 and 10 post infection. 
n= 5/6  
Lipid peroxidation was also investigated and expressed as pmol of 
malondialdehyde (MDA)/mg protein. MDA levels were significantly higher in 
livers from PbNK65-infected mice at day 8 and further increased at day 10 
post infection, while in PcAS infected mice they were similar to CTR at both 
days post infection (Figure 34). 
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Figure 34- MDA content in the liver of PbNK65 or PcAS infected mice 8 or 10 days 
post infection. 
n=6/8;  ***p<0,0001 vs CTR 
The activity of glutathione reductase (GR) was significantly enhanced at 
day 8 and 10 post infection in both parasite strains. SOD activity was 
similar to CTR at day 8 post infection but, with the progression of the 
pathology, its activity was significantly enhanced. Catalase (CAT) activity 
and total glutathione content increased at day 8 and 10 post infection in 
PcAS infected mice, while in PbNK65 infected mice they significantly 
decreased, compared to CTR, at day 10 post infection (Table 7). 
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Table 7- Enzymatic activities and total GSH content 
CAT GR SOD Total GSH 
mU/mg prot mU/mg prot U/mg prot nmol/mg prot
CTR 182,12 ± 23,1 108,48 ± 7,8 84,64 ± 27,2 87,43 ± 14,6
PcAS day 8 301,32 ± 59,2* 220,18 ± 5,4*** 99,98 ± 23,7 158,24 ± 3,5*
PcAS day10 284,15 ± 72,3** 260,97 ± 65,1*** 199,17 ± 54,5*** 165,62 ± 30,7***
PbNK65 day 8 236,31 ± 27,8 189,37 ± 35,7*** 74,57 ± 19,6 102,58 ± 17,0
PbNK65 day 10 121,17 ± 11,2* 162,7 ± 21,5*** 165,79 ± 34,1*** 65,06 ± 14,9**   
n=6; *p<0,05;**p<0,01; ***p<0,0001 vs CTR 
The lipid profile of livers of PbNK65 mice was significantly affected, 
showing higher levels of TG, free fatty acid (FFA) and ChoE, whereas free 
Cho was not significantly changed. These alterations were present at day 8 
and 10 post infection (Table 8). 
Table 8- Cholesterol (Cho), Cholesterol Esters (ChoE), Triacylglycerol (TG) and 
free fatty acid (FFA) content (mg lipid /g protein) in PcAs and PbNk65 infected mice 
at day 8 or 10 post infection. 
Cho ChoE TG FFA
CTR 18,99 ± 7,4 0,74 ± 0,6 25,92 ± 3,6 21,58 ± 6,5
PcAS day 8 34,86 ± 17,2 1,9 ± 1,3 37,4+19** 33,04 ± 7,5*
PcAS day10 28,6 ± 4,8 2,13 ± 1,8 55,81 ± 39,8 36,28 ± 19,0
PbNK65 day 8 26,24 ± 3,7 3,92 ± 2,5* 159,3 ± 54,3*** 46,87 ± 8,8***
PbNK65 day 10 18,9 ± 13,9 3,47 ± 0,3*** 144,79 ± 12,4*** 39,7 ± 16,6***  
n=6; *p<0,05; **p<0,01; ***p<0,0001 vs CTR 
In contrast, the total content of PL and the PL pattern were unchanged (not 
shown). The total fatty acid pattern of PbNK65 livers was characterized by 
higher levels of linoleic acid and lower levels of eicosatrienoic (C20:3 n-6) 
and arachidonic acids compared to CTR (Table 9). 
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The same fatty acid profile and differences compared to the CTR group 
were present in the isolated PC fraction (the most abundant, more than 
30% of the liver phospholipids). In addition, PC showed higher levels of 
DHA (9,0% vs 7,1% of CTR, p <0.05, not shown).  
Table 9- Fatty acid distribution (%) in liver 
CTR PcAS PbNK65
C16:0 22,76 ± 1,0 25,04 ± 0,8 * 20,39 ± 0,9 *
C16:1 1,4 ± 0,2 1,24 ± 0,1 0,63 ± 0,3 *
C18:0 14,25  ± 1,6 13,90 ± 0,7 14,47 ± 1,7
C18:1 11,34  ± 1,5 11,48± 1,5 12,67 ± 1,5
C18:2 n-6 17,93  ± 1,4 18,24 ± 0,6 24,32 ± 2,4 **
C18:3 α 0,34  ± 0,1 0,25 ± 0,1 0,24 ± 0,1
C18:3 γ 0,16  ± 0,1 0,15 ± 0,1 0,12 ± 0,1
C20:3 n-6 1,01 ± 0,1 0,95 ± 0,2 0,48 ± 0,1 ***
C20:4 n-6 21,82 ± 1,1 19,82 ± 0,8 * 17,41 ± 1,4 ***
C20:5 n-3 0,31 ± 0,1 0,24 ± 0,1 0,18 ± 0,1
C22:5 n-3 0,36 ± 0,1 0,52 ± 0,1 * 0,45 ± 0,1
C22:6 n-3 8,31 ± 0,7 8,16 ± 1,2 8,64 ± 0,6
PI 179,05 ± 8,9 170,34 ± 8,6 168,86 ± 9,4
C18:2/C20:4 0,82 ± 0,1 0,92 ± 0,1 * 1,41 ± 0,2 ***  
n= 4; *p<0,05; **p<0,01; ***p<0,001 vs CTR  
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5 DISCUSSION 
As outlined in the introduction, MA-ARDS is a common, often lethal 
pathological complication in adult patients with P.falciparum malaria. 
According to the WHO classification, deep breathing, respiratory distress 
and pulmonary oedema are among the clinical feature defining severe 
malaria (166). MA-ARDS is really important in malaria-endemic areas with 
low transmission (where adults get complications because they have no 
semi-immunity). In a survey conducted in India, malaria was the second 
cause of ARDS after sepsis (167). MA-ARDS is characterized by acute 
pulmonary inflammation, increased capillary endothelial and alveolar 
permeability leading to interstitial and alveolar oedema and hyaline-
membrane formation and results in ventilation-perfusion mismatch and 
impairment of gas exchange. The pronounced inflammatory response in 
MA-ARDS (both human and murine) is characterized by leukocyte and a 
limited number of neutrophil infiltration (130). Chronic and poorly regulated 
inflammation can often lead to fibrosis and macrophages are also 
considered important in this progression. The idea that inflammatory 
reactions may participate in the pathogenesis of MA-ARDS is reinforced by 
the fact that MA-ARDS is sometimes observed in patients with malaria 
during or even after treatment, when most of parasites are cleared from the 
circulation (112). 
We developed, in collaboration with professor Van den Steen of the 
University of Leuven, a new animal model for MA-ARDS with many 
similarities to human MA-ARDS. The infection of C57Bl/6 mice with P. 
berghei NK65 resulted in severe MA-ARDS with initial interstitial oedema 
and cell infiltration and progression to severe alveolar oedema, and the 
pathology developed to a full extent without cerebral malaria, creating a 
sufficient time window to study the pulmonary complications.  
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Lungs from PbNK65-infected mice had a brown-greyish colour due to 
hemorrhages and Hz deposition, in addition to significantly increased 
weights. The lung weight of PbNK65-infected mice was about twofold that 
of PcAS. This increase is due to the oedema formation and cells infiltration.  
Pulmonary Hz levels increased progressively during infection with PbNK65 
whereas lungs from PcAS-infected mice contained significantly less Hz. As 
previously demonstrated (130, 131) the strain-specific differences in 
pulmonary Hz levels were due to differences in Hz production by the 
parasite and not to differences in Hz degradation rate by the host. Even 
thought the amount of Hz decreased in the lungs after therapeutic parasite 
clearance, no Hz degradation was found during a four months observation 
period (168). 
Since Hz has inflammatory properties and tissue inflammation and cell 
migration are orchestrated by the expression of cytokines and chemokines, 
we measured mRNAs of some cytokines and in particular we studied the 
expression of TNF-α and IL-10 in lung homogenates at different times post 
infection. The comparison between PbNK65 and PcAS infections is 
important to discriminate between cytokines induced specifically during MA-
ARDS or as a consequence of systemic malaria infection. We found a 
major expression of TNF-α as well as IL-10 in the lungs of PbNK65-infected 
mice compared to mice infected with PcAS, indicating that these cytokines 
are induced specifically during MA-ARDS and they are not a consequence 
of the systemic malaria infection. The pulmonary expression of TNF-α and 
IL-10 present only in PbNK65 mice confirm the important role of Hz in 
pulmonary inflammation. The association between Hz, lung pathology and 
the induction of these mediators was determinated by Spearmen 
correlation analyses (data not shown). A positive correlation with both the 
amount of Hz/lung tissue and lung pathology was found for mRNA 
expression of TNF-α and IL-10 only in PbNK65-infected mice. Van de 
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Steen et al. demonstrated in a multiple regression model, that the 
relationship was statistically significant and was independent of sex and 
peripheral parasitaemia (131). A similar relation was found between Hz/mg 
lung tissue and lung weight and this relation was dependent on TNF-α and 
vascular endothelial growth factor (VEGF) (131).  
It’s known that TNF-α, induced in the lungs by Hz, can increase vascular 
permeability (128). Moreover, TNF-α reduces the pulmonary expression of 
the amiloride-sensitive epithelial sodium channel in the alveoli, thereby 
altering alveolar fluid clearance (136). Additionally, TNF-α triggers the 
release of NO, which can reduce alveolar epithelial sodium transport by 
reducing the activity of epithelial sodium channel and sodium/potassium 
ATPase (129). It has been shown that the alveolar epithelial sodium 
channel expression is also decreased during pulmonary pathology in mice 
infected with the P.berghei (136) and this may contribute to the observed 
interstitial oedema.  
The increased cytokine expression suggested that inflammatory reaction 
may participate in the pathogenesis of MA-ARDS. Therefore, in a different 
experiment we analyzed the effects of the anti-inflammatory DEX. The 
results showed that DEX is therapeutically effective against PbNK65 
induced MA-ARDS as indicated by the significant increased survival and 
reduced lung oedema. In agreement DEX reduced the pulmonary levels of 
some cytokines as IFN-γ. In addition to its known inhibitory influence on the 
expression of inflammatory cytokines, DEX exerted also an antiproliferative 
effect on leukocytes, in particular T lymphocytes. In fact in PbNK65 mice 
treated with DEX the number of CD8+ T lymphocytes was significantly 
decreased However, DEX treatment did not reduce the peripheral 
parasitaemia that was, on the contrary, slightly but significantly increased. 
Therefore, DEX inhibited MA-ARDS, not inhibiting parasite growth but 
rather modulating immunopathology. Altogether these data suggest that 
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anti- inflammatory treatment has the potential to improve the outcome of 
MA-ARDS. 
In addition to the inflammatory effects, Hz has a strong prooxidant activity 
(169). However, in spite of the high Hz concentration, in the present 
investigation we did not detect markers of increased lipid peroxidation, nor 
did we see signs of lung fibrosis. This is consistent with the particularly 
acute nature of MA-ARDS since fibroproliferation may progress in the 
second, more chronic phase of ARDS. In post-mortem analyses of patients 
with MA-ARDS, fibrosis is usually also not observed, although some 
exceptions have been reported of patients who died after a long chronic 
period of MA-ARDS and with interstitial pulmonary fibrosis (170, 171). 
In the membrane-enriched fraction of the pulmonary tissue of PbNK65-
infected mice we found a significant increase of the content of PL and 
ChoE. In particular the increase in the total content of PL is accounted by 
the higher levels of PC. The increase in lung PL is a common, although not 
universal response to alveolar inflammation and may be contributed to 
increased levels of intracellular surfactant (172). PC, the main PL of 
surfactant, is indeed increased in PbNK65-infected mice and contains a 
high percentage of palmitic acid, the most abundant fatty acid of surfactant 
(48%, not shown). The PL and ChoE levels of lung homogenates  were 
significantly higher when the lungs were dissected without previous 
perfusion. In this case PE was also significantly increased. This 
phospholipid was present in higher concentrations also in plasma of 
PbNK65 infected mice suggesting a correlation with interstitial oedema and 
lipoprotein infiltration during MA-ARDS. This hypothesis was confirmed by 
the observation that PL and ChoE were not increased in PcAS-infected 
mice whereas they are reverted by DEX treatment in PbNK65-infected 
mice. Lipoprotein infiltration is suggested also by the fatty acid composition 
of ChoE from PbNK65-infected lungs, reflecting the peculiar fatty acid 
93 
 
composition of PbNK65 ChoE in plasma: high linoleic acid arachidonic acid 
(AA) and DHA fatty acids and high ratio linoleic/oleic fatty acids (173). The 
high linoleic/oleic ratio is typical of plasma ChoE where the majority of 
ChoE derives from the activity of the plasma Lecithin Cholesterol AcylCoA 
Transferase (LCAT) highly specific for linoleic acid rather than from the 
hepatic AcylCoA Cholesterol Acyl Transferase (ACAT) activity, more 
specific for oleic acid. On the contrary, the high level of DHA observed not 
only in the lung of PbNK65-infected mice but also in PcAS-infected mice 
and not reverted by DEX, merely reflects the high levels of DHA present in 
plasma excluding a correlation with the malaria caused lung pathology. 
Since ARDS is often associated with surfactant disorder we investigated 
the changes in lung surfactant of infected and non infected mice.  
Proposed mechanisms of lung surfactant disorders in ARDS include 
destruction of the air-water interface by alveolar oedema, phospholipid and 
protein degradation by secretory phospholipases and proteases (174), and 
decreased synthesis of surfactant components by damaged type II cells 
(175). Leakage of plasma proteins into the alveoli is thought to contribute to 
the lower alveolar stability (176).  
In PbNK65-infected mice, oedema and alveolar leakage due to the lung 
pathology are responsible for increased protein levels, either in the total 
cell-free BAL fraction or in the BAL LA fraction, probably due to blood-
derived proteins being incorporated into or associated with these 
microstructures in the alveolar hypophase. Van den Steen et al. (130) 
demonstrated that the protein profile of BAL fluid was comparable with that 
of plasma. At day 10 post infection with PbNK65 a considerable volume of 
plasma had leaked out from the blood vessels into alveoli. Concurrent with 
the oedema formation and alveolar leakage, the protein concentration of 
plasma was significantly decreased in PbNK65-infected mice (130). 
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The different leukocyte subpopulations of BAL fluid, calculated by 
microscopy enumeration of  Cytospin preparations, were significantly 
increased already from day 8 post infection with PbNK65, showing that 
large numbers of leukocytes had infiltrated into the alveoli during PbNK65 
induced MA-ARDS. The leukocyte infiltration confirmed the already 
discussed hypothesis i.e that inflammatory reactions participate in the 
pathogenesis of MA-ARDS.  
It’s well known that oedema formation and blood protein infiltration 
decrease the intrinsic surface activity of LA fraction that represents the 
more active form of surfactant (177). A lower surface activity may also 
contribute to pathology in PbNK65-infected mice, as indicated by the 
altered PL profile of the LA fraction, characterized since day 8 post infection 
by higher levels of SM and lower levels of PG. PG was dramatically 
decreased also in the SA fraction where it was almost undetectable. These 
changes have been reported also in other animal models of lung injury and 
in patients with established ARDS (178, 179) and may be related to the 
altered surfactant reuptake and synthesis by injured alveolar cells or to PL 
contamination due to inflammatory cells or damaged alveolar type II cells. 
The increase of lysophosphatidylcholine (LPC), a known inhibitor of 
surfactant activity (180), in the SA fraction is consistent with the action of 
secretory phospholipases A2 (sPLA2) whose activity has been detected in 
ARDS patients in BAL fluid, in particular in the SA aggregates (181). 
Interestingly, it has been suggested that during severe liver pathology, as 
that demonstrated in the present work in PbNK65 mice, sPLA2 may be 
activated and related to lung injury (182). Since plasma reflects the status 
of host homeostasis and it’s also an excellent reporter of disturbances 
caused by environmental stressors we the content and composition of 
plasma lipids was also investigated. 
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As expected, in PbNK65-infected mice the lipid profile of plasma appeared 
altered as well. Most of the observed alterations may be related to a 
delayed catabolism of VLDL due to the TNF-α induced reduction of 
lipoprotein lipase (LPL) activity (183). The impairment of LPL activity in 
PbNK65-infected mice may account for the higher levels of TG and Cho, as 
well as PE. In fact, PE is a phospholipid enriched in nascent VLDL particles 
and is cleared from the plasma during the metabolism of VLDL by LPL and 
the delivery to high density lipoprotein (HDL), by the action of hepatic lipase 
(HL) (184). Interestingly, HL activity too has been found to be reduced in 
some models of infection and inflammation (185, 186). Likewise, a delayed 
VLDL catabolism may account for the increase of plasma SM whose 
plasma concentration is higher in hyperlipidemia models related to infection 
and inflammation (187). These models are characterized by a higher 
Cho/ChoE ratio and an increased VLDL production and/or a delayed VLDL 
clearance (187, 188). In addition, high levels of TNF-α have been shown to 
reduce LCAT activity (188). In PbNK65-infected mice, a lower activity of 
LCAT can be hypothesized from the lower percentage of plasma LPC and 
the higher Cho/ChoE ratio.  
The fatty acid profile of the total lipids from plasma was in good agreement 
with the literature (189). Since the three main lipid classes (PL, TG and 
ChoE) of plasma have a peculiar fatty acid pattern, the change in their 
concentration or their molecular species can account for differences in total 
plasma fatty acids. The most important observation was the higher levels of 
polyunsaturated fatty acids (PUFA), in particular DHA, that may be related 
to the higher proportion of PE, the phospholipid carrying the most of this 
fatty acid, as confirmed by the higher DHA level also in the isolated PL 
fraction (not shown). The DHA levels were only partially reverted by DEX 
treatment. This finding suggests that their increase is not related to lung 
pathology but rather to the malaria infection. 
96 
 
The fatty acid composition of plasma ChoE showed an higher proportions 
of linoleic acid than oleic acid, suggesting that also in PbNK65-infected 
mice the majority of plasma ChoE derives from LCAT rather than ACAT 
activity (190). 
In agreement with literature, our findings on plasma lipid alterations 
demonstrated that infection or inflammation can severely impair the activity 
of enzymes involved in the metabolism of lipoprotein. Together with a 
delayed or modified metabolism of lipoproteins, the increase of plasma 
lipids may be due to an enhanced hepatic lipogenesis. To verify this last 
hypothesis we found of interest to extend our investigation to liver tissue. 
The incidence of hepatopathy is high in patients with severe malaria and 
MA-ARDS (191) and it is characterized by Kupffer cell hyperplasia with 
haemozoin deposition. In our models of murine infection hepatomegaly was 
observed with both parasite strains at day 8 post infection while, 10 days 
post infection hepatomegaly was present only in PcAS infected mice, 
whereas liver weights were slightly decreased in P.berghey NK65. The 
infected mice liver showed also a decrease in total protein contents. This 
finding suggests that continuous extensive proteolysis may provide a 
readily available pool of free amino acids to parasites for their rapid 
proliferation.  
Upon intraerythrocytic parasite replication and subsequent schizont rupture, 
newly formed merozoites are released into the blood together with high 
amounts of Hz, which are rapidly removed by phagocytosis. The liver 
significantly contributes to the phagocytosis of infected RBC and Hz, as 
evidenced by the high hepatic Hz levels. The amount of Hz/mg liver tissue 
was higher in PbNK65 mice and the level progressively increased during 
infection, indicating that when infection progresses, more Hz is released 
into the circulation and trapped in the liver. To analyze whether liver 
histology is differently affected by the two parasite strains, cryosections 
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from perfused livers were stained with hematoxylin-eosin. No major 
morphological changes were noticeable in the liver architecture of both 
PbNK65 or PcAS infected mice, but the livers of PbNK65 mice 10 days 
after infection contained more abundant and larger clusters of Hz, than 
livers from PcAs infected mice, corroborating the Hz quantification data. 
Higher levels of TNF-α, as mRNA and protein, were detected in PbNK65-
infected mice compared to PcAS group. TNF-α expression was correlated 
to Hz deposition. Hz levels, which are significantly higher in PbNK65-
infected mice than in mice with a self-resolving PcAS infection, may 
activate Kupffer cells to release TNF-α, which may be involved in liver 
damage and may play a key role, in the early stages, in the lipogenetic 
activity of the liver (192). Infection and inflammation have been shown to 
induce multiple alterations in hepatic lipid and lipoprotein metabolism (186). 
In fact, in rodents TNF-α rapidly increases adipose tissue lipolysis and 
hepatic fatty acid, Cho and TG synthesis (186, 193) and hepatic lipotoxicity, 
at least in part, by inducing hepatocyte lysosomial destabilization (194). In 
agreement with these findings we have observed important alterations in 
liver lipids of PbNK65-infected mice. The significant increase of TG, FFA 
and ChoE in PbNK65-infected livers is in agreement with literature data 
showing that livers from P. berghei-infected mice contain lipid droplets and 
myelin-like figures (151) and suggesting that malaria parasites are able to 
influence the hepatic lipogenesis. 
In addition, TNF-α damages the mitochondrial membrane enhancing the 
production of anion superoxide radicals and therefore reactive oxygen 
species (ROS) and triggering a vicious cycle since it has been proposed 
that ROS further promotes TNF-α synthesis through the activation of NF-kB 
transcription factor (185). Subsequently, mitochondria themselves become 
the target of ROS, thereby promoting, through the further impairment of the 
electron flow, the production of other radicals and inducing lipoperoxidation 
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of unsaturated lipids in hepatic fat deposits. ROS-induced lipoperoxidation 
and/or ROS-induced impairment of the elongation/desaturation pathway 
from linoleic acid (LA) to arachidonic acid (AA) (195), may explain the 
higher LA/AA ratio in the liver of PbNK65-infected mice. The higher 
production of ROS in PbNK65-infected mice was evidenced by the elevated 
MDA concentration present at day 8 and 10 post infection. MDA remained 
similar to CTR in PcAS-infected mice. We studied also the enzymes 
involved in the antioxidant defence and we found that catalase activity in 
both parasite strains increased at day 8 post infection. With the progression 
of the pathology (10 days post infection) in PbNK65 infected mice, the 
activity of the enzyme decreased becoming significantly lower than CTR.  
A similar trend was observed for hepatic glutathione levels while SOD 
activity increases only at day 10 post infection in both parasite strains. GR 
and SOD are known to exert a protective role in minimizing oxidative 
stress, largely derived from the production of superoxide anion radicals. 
These findings suggest that the increase of ROS may initially trigger the 
elevation of the endogenous antioxidant defences that are later depleted 
due to the liver damage caused by the aggressive progression of the 
pathology.  
Imbalances in the oxidative status of PbNK65-infected livers may be 
involved in the progression of liver disease. In fact, it is known that the 
expression of transforming growth factor-β (TGF-β) is enhanced in ROS-
activated macrophages (192). In turn, TGF-β plays a role in the recruitment 
of neutrophils and in the activation of hepatic stellate cells, which increase 
the secretion of type I collagen (196). This contributes to the development 
of hepatic fibrosis, as shown in PbNK65-infected mice by the high hepatic 
levels of hydroxyproline. Submicroscopical signs of fibrosis, determinated 
by hydroxyproline quantification analyses, were evident not only in PbNK65 
infected mice but also, although at a lower level, in PcAS group, starting 
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from day 8 post infection. Interestingly, at day 10 post infection the quantity 
of hydroxyproline decreased in both parasite strains, becoming similar to 
CTR mice. The hypothesis that inflammation may lead to the activation of 
metalloproteinase (MMPs) is under investigation. MMPs are proteolytic 
enzymes able to degrade different proteins of the extracellular matrix (e.g. 
collagen, laminin, fibronectin) and modulate cytokine and chemokine 
activity in a variety of physiological processes and pathological conditions 
such as inflammation. Van de Steen et al demonstrated, in the liver of 
C57Bl/6J mice infected with PbNK65, a significant increase of the activity of 
MMPs (197). Furthermore several in vitro studies have shown an induction 
TNF-α dependent of MMPs mRNA and protein by monocytes fed with 
natural Hz (198-200). 
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6 CONCLUSIONS 
We performed a comprehensive analyses of the lipid content and 
inflammatory response of different organs in a murine model of MA-ARDS. 
Hypoxia, cytoadhesion and inflammation, all observed in the lung of our 
model, can deregulated or disrupt the alveola endothelial barrier resulting in 
extravasation of protein rich fluid characteristic of vascular hyper-
permeability. Under normal circumstances, increases in vascular 
permeability result in leakage of protein rich fluid into perivascular spaces 
between the vasculature and the alveoli with subsequent fluid removal by 
the lymphatic system. However, when fluid filtration exceeds fluid removal, 
vasogenic oedema develops as is observed in both mice and patients with 
MA-ARDS (63,112). 
The precise mediators responsible for this hyper-permeability state and the 
pathways by which molecules can cross the endothelial barrier under 
pathologic circumstances are heterogeneous and not well understood.  
In our model we found an imbalance between immune mechanisms 
generated by the host and immune evasion mechanisms by the parasite, in 
particular there is an increase in the lung expression of several cytokines 
(TNF-α; IL-10; IFN-γ) and leukocyte and macrophages infiltrations. Since 
natural Hz has multiple effects on monocytes in vitro, and was localized 
insides monocytes and macrophages in lung, we investigated whether Hz 
might have a role in the pathogenesis of malaria complications. The 
symptoms of lung pathology are more severe in C57Bl/6J mice infected 
with the PbNK65 strain which succumb from MA-ARDS. In particular 
cytokines and chemokines are increased in the lung of PbNK65 infected 
mice and lipids of lung tissue and bronchoalveolar lavage fluid are 
qualitative and quantitative changed. At the same time in the liver of 
PbNK65 infected mice are present high levels of Hz.  
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When we investigated Hz levels and disease parameters we found a strong 
correlation between Hz concentration and pulmonary or hepatic pathology. 
These results suggest that Hz might have a pathological role in these 
complications. Hz is not an inert crystal, due to the presence of multiple 
Fe3+ ions in the haemin components constituting the Hz crystals, and 
causes lipoperoxidation when interacting with membranes containing 
polyunsaturated fatty acids. The different lipoperoxidation products and 
reactive oxygen species (ROS) that are generated during this process may 
have opposite effects, since both inhibition of important monocyte functions 
(such as phagocitosis and antigen presentation), and the induction of pro-
inflammatory cytokine expression, in particular TNF-α, through nuclear 
factor-κB (NF-Kb) activation (132, 200). TNF-α on the one hand damages 
mitochondrial membrane further enhancing the production of ROS, on the 
other one induces lipogenesis conducing to steatosis. Subsequently, 
mitochondria themselves become the target of ROS, thereby promoting, 
through the further impairment of the electron flow, the production of other 
radicals and inducing lipoperoxidation of unsaturated lipids in hepatic fat 
deposits.  
We demonstrated a pulmonary-liver metabolic interplay in wich Hz is not 
merely a waste product of the metabolic activity of the parasite, but it is an 
important inflammatory virulence factor. The pathogenesis of the lung 
tissue injury, is related to the hepatic generation of the pro-inflammatory 
cytokine TNF-α. TNF-α, generated by liver, translocates to lung where it 
initiates a mediator cascade result in pulmonary neutrophil accumulation 
and ensuing lung injury.  
Since inflammation plays an important role in different organs, may be 
worthwhile to test anti-inflammatory drugs in clinical trials in addition to anti-
malaria drugs. 
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